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The establishment of tyrosine kinase inhibitors (TKIs) has revolutionized the 
treatment of chronic myeloid leukemia (CML) during the last fifteen years. 
This study explored the journey of 86 patients with CML using oral TKI 
treatment in Finland. The aim was to assess their adherence to TKIs and how 
the adherence, which is crucial for treatment outcomes, could be improved.   
 
This study applied quantitative and qualitative methods and a randomized 
controlled study design during 2012-2014. All patients participated in the in-
person interview, which followed the idea of the patient’s journey with CML 
from the time before diagnosis to the study point. Patient-reported adherence 
was evaluated using Morisky’s 8-Item Medication Adherence Scale (MMAS) (I-
IV). Physicians were also asked to assess their patients’ adherence. Patient-
reported adverse drug reactions (ADRs) and quality of life (QoL) were assessed 
during the interview using a structured questionnaire (II, III). The patient’s 
knowledge of the disease and TKI treatment was evaluated by asking five key 
questions (I, III, IV).  
 
The intervention with 9-month follow-up in Study IV was based on tailored 
patient education combining nurse-conducted face-to-face counseling, 
educational video, patient booklet, website and text message reminders. The 
intervention material had the following learning objectives: CML as a disease, 
goals for TKI treatment, the importance of taking TKI medication as 
prescribed, and self-management of ADRs. 
 
A total of 86 patients participated in the study (approximately 20% of all 
Finnish CML patients). Of the patients enrolled, 43 were randomized into the 
intervention group and 43 into the control group (IV). A total of 68 patients 
completed the study. 
The results show that the response to TKI treatment was high (I), with 81% of 
the patients showing an optimal response to their treatment according to 
European LeukemiaNet 2013 recommendations. The CML patients’ knowledge 
of the disease and its treatment was poor (I). Despite the high molecular 
response rates to TKIs, adherence was not good in most of the patients: less 
than a quarter (23%) showed high adherence, 56% medium adherence, and 
21% low adherence (I). Adherence was not influenced by patients’ gender, age, 
education, knowledge, time from diagnosis, ADRs, number of comorbidities or 
number of other medications. There was a considerable difference between 
observed and experienced adherence: 94% of the patients were highly 
adherent according to the physicians’ assessment, compared to 23% (I). 
The most common reason for unintentional non-adherence was forgetting to 
take the medication (I, III, IV). In the interviews patients reported self-
regulation of medication taking, particularly on those occasions where patients 
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wanted to avoid ADRs (III). The incidence of patient-reported ADRs was high 
(II). At the time of the study 97% of the patients reported suffering from at 
least one ADR, most commonly muscle soreness or cramp (80%), swelling of 
hands, legs, feet, or around the eyes (69%), and fatigue (50%). 
Patient interviews indicated that ADRs were the most common barriers to 
adherence (III). More than half of the patients felt the ADRs had a negative 
influence on their daily QoL (II). Compared with the total study group, the 
incidences of almost all symptoms were higher among patients whose 
symptoms negatively affected their daily life than those who reported no such 
influence (II).  
 
The patient journey model developed in the study (III) identified the following 
critical phases in the CML patient’s journey: getting the diagnosis, starting the 
treatment, getting continuous support for treatment self-management, and 
managing fear caused by perceived severity of the disease. Even though only 
44% of the low-adherent patients in the study experienced the TKI treatment 
as inconvenient, most of the patients (94%) were willing to stop taking the 
medication in the future if possible (III).  
All CML patients in the study were lacking a treatment plan and only a few had 
a medication list (I, III). The knowledge test (I, III) showed that patients had a 
poor understanding of their disease and its treatment, while low-adherent 
patients indicated that understanding the consequences of not taking the 
medication and the goal for the treatment would be motivating factors to 
adhere to the medication (III). 
 
The intervention significantly improved adherence (IV). In the intervention 
group the MMAS score increased more often than in the control group 
(p=0.001). The MMAS score declined in almost half of the patients in the 
control group, but only in 9% of those in the intervention group (p=0.001). A 
majority of the patients found the intervention useful, the most useful parts 
being face-to-face counseling and the educational booklet. Text messages were 
least valued. 
 
The findings of this study suggest that non-adherence is common among 
Finnish CML patients and that physicians seem to be too optimistic in 
assessing their patients’ adherence. The complex interplay between symptom 
burden, adherence, self-regulation, managing with ADRs, response to TKI 
therapy, and healthcare utilization highlights the need for regular symptom 
burden assessment in CML as a means to identify potential adherence 
problems before they affect the patients’ response to TKI treatment.  
Tailored patient education improved the adherence of patients with CML after 
a 9-month follow-up. Without the additional support, adherence behavior 
tended to decline. Patients were most satisfied with face-to-face counseling by 
the nurse, which means they need personal support and practical aids to help 
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them manage their medication in everyday life. Access to personal counseling 
and information should be systematically planned as an essential part of CML 
care. Appropriate and updated information in printed and electronic formats 
should be available for nurses and other healthcare personnel to enable them 
to support their patients.  
 
The findings of this study suggest that patients’ perceptions and preferences 
should be understood and taken into account when designing patient 
education interventions for real-life clinical practice. The findings also 
highlight the need to further evaluate the interventions to enhance adherence. 
There is a need for communication to increase patients’ abilities to follow their 
treatment plan throughout their journey, which requires real partnership 
between healthcare professionals and patients. 
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Adherence 
According to the World Health Organization (WHO) (2003): “the extent to 
which a person’s behaviour – taking medication, following a diet, and/or 
executing lifestyle changes, corresponds with agreed recommendations from 
a healthcare provider” (Sabaté 2003). 
 
Adverse drug reaction (ADR) 
According to Edwards and Aronson (2000): “an appreciably harmful or 
unpleasant reaction, resulting from an intervention related to the use of a 
medicinal product, which predicts hazard from future administration and 
warrants prevention or specific treatment, or alteration of the dosage 
regimen, or withdrawal of the product.” 
 
Chronic myeloid leukemia (CML) 
Chronic myeloid leukemia (CML) is a clonal disease of the hematopoietic stem 
cells in the bone marrow, which leads to a marked proliferation of granulocytes 
in the blood (Goldman and Melo 2003). About 20–45% of patients are 
asymptomatic at diagnosis and are picked up incidentally from examination of 
the peripheral blood. The most common clinical features include fatigue, 
weight loss, loss of appetite, abdominal fullness, splenomegaly, anemia, 
bruising and sweats (Savage et al. 1997, Faderl et al. 1999). 
 
Morisky’s adherence scales 
Morisky’s adherence scales are structured, self-reported scales for assessing 
medication adherence. There are two different Morisky Adherence Scales: a 
four-item self-reported questionnaire (Morisky et al. 1986) and an eight-item 
self-reported scale called the Morisky Medication Adherence Scale (MMAS) 
(Morisky et al. 2008).  
 
Quality of life (QoL) 
According to the World Health Organization (WHO) “individuals’ perception 
of their position in life in the context of the culture and value systems in which 
they live and in relation to their goals, expectations, standards and concerns” 
(WHOQOL Group 1994).  
 
Tyrosine kinases 
Tyrosine kinases are enzymes that catalyze the transfer of the gamma 
phosphate group from adenosine triphosphate to target proteins. They play an 
important role in diverse normal cellular regulatory processes. Tyrosine 
kinases can be classified as receptor protein kinases and nonreceptor protein 
kinases. Receptor tyrosine kinases are transmembrane cell surface proteins 
that play critical roles in the transduction of extracellular signals to the 
 15
cytoplasm (Pawson 2002). Tyrosine kinases are important mediators of the 
signaling cascade, determining key functions in diverse biological processes 
like growth, differentiation, metabolism, and apoptosis in response to external 
and internal stimuli. Deregulation of protein kinase activity has been shown to 
play a central role in the pathogenesis of human cancers (Melo and Goldman 
2007). See also definition of Tyrosine kinase inhibitor. 
 
Tyrosine kinase inhibitor (TKI) 
A tyrosine kinase inhibitor (eg. imatinib, dasatinib or nilotinib) is a small 
molecular substance, which inhibits the high tyrosine kinase activity of cancer 
cells by inhibiting ATP or substrate binding and which directly affect the 
kinase activity (Melo and Goldman 2007). See also definition of Tyrosine 
kinases. 
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ADR  Adverse drug reaction 
ALL  Acute lymphatic leukemia 
alloSCT  Allogeneic stem cell transplantation 
ALT  Alanine transaminase 
AML  Acute myeloid leukemia 
ASH  American Society of Hematology 
AST  Aspartate transaminase 
ATP Adenosine triphosphate 
BCR-ABL Bcr-Abl fusion gene (human) 
Bcr-abl Bcr-Abl fusion gene (mice) 
CCyR  Complete cytogenetic response  
CHR  Complete hematological response 
CML  Chronic myeloid leukemia 
CML-AP  Accelerated phase of chronic myeloid leukemia 
CML-BC  Blast crisis phase of chronic myeloid leukemia 
CML-CP  Chronic phase of chronic myeloid leukemia 
CLL  Chronic lymphocytic leukemia 
CRO Clinician reported outcome 
ELN  European LeukemiaNet 
EMA  European Medicines Agency 
EORTC  European Organisation for Research and Treatment of Cancer 
FACT-Leu Functional assessment of cancer therapy – leukemia 
FDA  Food and Drug Administration (US) 
FIMEA  Finnish Medicines Agency 
FISH  Fluorescence in situ hybridization  
GI  Gastrointestinal 
IC50 Half maximal inhibitory concentration 
IFN  Interferon 
Kela  Kansaneläkelaitos (Finnish Social Insurance Institution) 
MDASI-CML M.D. Anderson symptom inventory-CML 
MEMS Medication event monitoring system 
MMAS Morisky Medication Adherence Scale 
MMR  Major molecular response 
MPR Medication possession ratio  
MR3  Molecular response with a reduction of 3 log  
MR4  Molecular response with a reduction of 4 log  
MR4.5  Molecular response with a reduction of 4.5 log  
MR5  Molecular response with a reduction of 5 log  
NME Negative medication experience 
OS  Overall survival 
PAH  Pulmonary arterial hypertension 
PAOD Peripheral arterial occlusive disease 
PCR  Polymerase chain reaction 
Ph  Philadelphia chromosome 
Ph+  Philadelphia-chromosome-positive 
PFS Progression-free survival 
PRO  Patient-reported outcome 
QLQ-CML24  Quality of life module for chronic myeloid leukemia 
QoL  Quality of life 
qRT-PCR  Quantitative reverse-transcription polymerase chain reaction     
QT Measure of the time between the start of the Q wave and the end of the T wave in the heart's electrical cycle in 
electrocardiogram 
QTc Corrected QT interval 
RCT  Randomized controlled trial 
rIFNa  Recombinant interferon alpha 
SCT  Stem cell transplantation 
SPC Summary of product characteristics 
TFR  Treatment-free remission  
TKI  Tyrosine kinase inhibitor 
UK  United Kingdom 
UMD  Undetectable molecular disease 
URT  Upper respiratory tract 
US  United States  
VAS Visual analogue scale  
WHO  World Health Organization 
?
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Chronic myeloid leukemia (CML) is a clonal disease of the hematopoietic stem 
cells in bone marrow, which leads to a marked proliferation of granulocytes in 
the blood (Goldman and Melo 2003). The annual incidence of CML in Finland 
and worldwide is the same, about 1 to 2 new cases per 100,000 individuals 
(Ruutu et al. 2002). In most cases the disease is diagnosed during further 
investigations of an abnormal blood count. At that time, the disease is usually 
in an asymptomatic chronic phase (Goldman and Melo 2003). The most 
common clinical features include fatigue, weight loss, loss of appetite, 
abdominal fullness, splenomegaly, anemia, bruising and sweats (Savage et al. 
1997, Faderl et al. 1999). 
Introduction of the first tyrosine kinase inhibitor (TKI), imatinib, caused a 
dramatic change in the management of CML more than ten years ago (Stone 
2004). The prognosis of the patients improved and treatment moved from 
hospitals to patients’ homes. During the last five years, several second- and 
third-generation TKIs (dasatinib, nilotinib, bosutinib and ponatinib) have 
been developed, giving physicians even more options to treat CML patients. 
Left untreated, CML is inevitably fatal. However, the excellent results of TKI 
treatment (O’Brien et al. 2003, Kantarjian et al. 2012, Baccarani et al. 2013, 
Ross and Hughes 2014) are raising the legitimate expectation that a 
considerable number of patients will achieve treatment-free remission (TFR). 
The prevalence of patients with CML treated with TKIs is expected to increase 
by about 10% per year, so that CML is a challenge for healthcare systems 
worldwide (O’Brien et al. 2003, Storey 2009, Huang et al. 2012, Baccarani et 
al. 2013). 
The World Health Organization (WHO) has defined adherence as “the extent 
to which a person’s behavior – taking medication, following a diet, and/or 
executing lifestyle changes – corresponds with agreed recommendations from 
a health care provider” (Sabaté 2003). In order to achieve clinical responses in 
CML, medication adherence is crucial (Darkow et al. 2007). Previous studies 
have shown that lack of adherence to TKIs is frequent and has a significant 
impact on the degree of response to therapy obtained by the patient (Noens et 
al. 2009, Marin et al. 2010, Ibrahim et al. 2011). Marin et al. (2010) found no 
molecular responses when adherence was less than 80%.  
For most patients, non-adherence to cancer therapy is due to several factors 
(e.g. treatment, patient, healthcare provider) present either at the same time or 
sequentially (D’Amato 2008, Doucette et al.  2012). Few previous studies have 
assessed CML patients’ reasons for non-adherence to TKI treatment (Eliasson 
et al. 2011, Efficace et al. 2012, Efficace et al. 2014). These studies have 
primarily focused on quantitatively investigating patient and healthcare 
provider characteristics that impact on adherence to TKIs in CML patients 
(Noens et al. 2009, Efficace et al. 2012a, Efficace et al. 2014). Patient 
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characteristics that have been found to affect CML patients’ adherence to TKIs 
are forgetfulness, patient education, knowledge and understanding, and 
patients’ physical and emotional feelings (Hall et al. 2016). When asked about 
their poor adherence to imatinib therapy, CML patients report unintentional 
(forgetfulness, prescribing error, drug availability) and intentional (adverse 
effects, social events, travel, temporary illness, negative feelings, medication 
taste) reasons (Eliasson et al. 2011). 
Eliasson et al. (2011) found that patients who reported intentional reasons for 
non-adherence had greater symptom severity than patients who reported 
unintentional reasons.  Marin et al. (2010) found significantly lower rates of 
adherence to imatinib among patients who reported adverse drug reactions 
(ADRs). 
A standardized collection of health-related quality of life (QoL) data and other 
patient-reported outcomes (PROs) has contributed to a better understanding 
of overall treatment effectiveness in patients with solid tumors (Phillips et al. 
2013, Trask et al. 2013), but such evidence is lacking in patients with leukemia 
(Aziz et al. 2011, Efficace et al. 2012b).  PROs are defined by the FDA as “a 
measurement of any aspect of a patient’s health status that comes directly from 
the patient” (i.e., without the interpretation of the patient’s responses by a 
physician or anyone else) (FDA 2009).  Documenting QoL and the adverse 
effects of CML treatments from the patients’ perspective is necessary to 
evaluate overall treatment effectiveness and the net clinical benefits of newer 
therapeutic strategies (Efficace et al. 2012c).  A patient-centered approach to 
determining the symptoms most relevant to patients with CML is supported by 
recent findings showing that healthcare providers tend to underestimate the 
intensity of symptoms felt by patients with advanced cancer (Laugsand et al. 
2010). While the impact of TKIs from the patient’s perspective has been little 
investigated, PROs could be critical for making more informed treatment 
decisions, as all TKIs seem to provide similar excellent clinical outcomes 
(Hocchaus et al. 2009, Kantarjian et al. 2012, Larson et al. 2012).  More 
attention has been placed on understanding the impact of symptom burden on 
patient QoL. At the time this study was conducted, however, validated 
instruments to measure QoL in CML were not available or regularly used in 
clinical research or routine practice.  
Patients with CML progress through five distinct stages in their disease 
experience: crisis, hope, adaptation, new normalcy, and uncertainty (Guilhot et 
al. 2013). Ability to cope with these stages, which could be called ‘a patient 
journey’, is affected by the degree of knowledge about the disease, comfort 
level with the physician, and optimism about the success of the treatment  
(Guilhot et al. 2013). Despite the work of Guilhot et al., the journey of patients 
with CML is not well understood. Two recent studies have focused on assessing 
the impact of patient-reported treatment restrictions and negative medication 
experiences (NMEs) on satisfaction and other health outcomes of CML 
patients taking TKIs (Hirji et al. 2013) and on patients’ experiences of their 
care, doctor-patient relationship and relationship with family and friends 
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(Hamerschlak et al. 2015). 
No single type of intervention is likely to be successful in improving adherence 
(Osterberg and Blaschke 2005, Possidente et al. 2005, D’Amato 2008). 
Successful interventions have been based on improving patient education and 
communication between patient and medical staff, simplifying medication 
regimens and using cues to remind patients of dosing schedules (Osterberg 
and Blaschke 2005). According to previous studies, using multiple 
interventions and different adherence aids over time may be the most 
successful approach (Johnson A et al. 2003, Touchette and Shapiro 2008). 
There is little evidence to show that educational interventions influence CML 
patients’ adherence to TKIs, and only one such study has previously been 
published (Moon et al. 2012).  
This thesis concerns the journey of 86 patients with CML in Finland primarily 
from the perspective of adherence. The first publication concerning a high level 
of non-adherence to TKIs became available in 2009 (Noens et al. 2009). At 
that time there was no information about patients’ reasons for not adhering to 
TKIs. The literature provides limited information on how to improve 
adherence among CML patients, and there is no previous work assessing 
adherence from multiple viewpoints. The overall aim of this thesis is therefore 
to provide tools to improve the adherence and lives of patients with CML.   
This thesis consists of two parts: a literature review and an empirical section. 
The literature review provides the contextual framework for the empirical part 
(Chapter 6). It covers the introduction to CML as a disease (Chapter 2), its 
treatments (Chapter 3), monitoring the treatment response (Chapter 3) and an 
overview of ADRs related to TKIs. It also describes the QoL associated with 
TKI treatments (Chapter 3) and the patient path in the healthcare system in 
Finland (Chapter 4). The world of medication adherence is evaluated in 
Chapter 5, which also covers current knowledge of the interventions that 
enhance medication adherence. 
The empirical part of the thesis investigates the journey of CML patients in 
Finland: patients’ experience on their journey with CML, adherence to TKIs, 
patient-reported ADRs, and QoL (Studies I-IV). These perspectives were 
chosen because they are relevant for understanding the background and 
consequences of adherence. Currently, the literature provides no information 
on these subjects in Finland. Finally, the influence of tailored patient 
education on adherence to TKI medication among patients with CML is 
investigated (Study IV). 
 
?
?
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2  CML  
2.1 Leukemias 
Leukemia is a cancer that starts in the blood-forming cells of the bone marrow 
(Wetzler et al. 2005, White and Walker 2007). There are four main types of 
leukemia: acute myeloid leukemia (AML), chronic myeloid leukemia (CML), 
acute lymphocytic leukemia (ALL) and chronic lymphocytic leukemia (CLL) 
(Wetzler et al. 2005, White and Walker 2007). This thesis concentrates on 
patients with CML. 
 
2.2 CML as a disease 
 
CML is a clonal disease of the hematopoietic stem cells in the bone marrow, 
which leads to a marked proliferation of granulocytes in the blood (Goldman 
and Melo 2003). The first case of CML was described in 1845 by John Hughes 
Bennett and Rudolph Virchow (Bennett 1845, Virchow 1846). Myeloid 
leukemias (also known as myelocytic, myelogenous, or non-lymphocytic 
leukemias) start in early myeloid cells - the cells that become white blood cells 
(other than lymphocytes), red blood cells, or platelet-making cells 
(megakaryocytes) (Goldman and Melo 2003).  
 
2.2.1 Philadelphia chromosome  
CML differs significantly from the three other main types of leukemia: in 
almost all patients (95%), CML is characterized by a specific chromosome 
translocation known as the Philadelphia (Ph) chromosome (Nowell and 
Hungerford 1960, Rowley et al. 1973, Sawyers 1999). This chromosome is 
formed by a reciprocal translocation between the long arms of chromosomes 9 
and 22 and carries a unique BCR-ABL fusion gene (Figure 1). The BCR-ABL 
gene encodes a constitutively active protein, tyrosine kinase. Elevated and 
abnormal activity of BCR-ABL tyrosine kinase leads to a massive increase in 
the number of myeloid cells (Druker 2008). The mechanism that leads to the 
formation of the Ph chromosome is unknown (Goldman and Melo 2003). The 
link between the Ph chromosome and CML was discovered in 1960 (Nowell 
and Hungerford 1960). 
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Chromosome 9 Chromosome 22 Philadelphia (Ph) chromosome 
                                                                           
 
ABL gene      + BCR gene        =             Fusion gene (BCR and ABL combined) 
 
Figure 1. Reciprocal translocation between the long arms of chromosomes 9 and 22 forms the     
Philadelphia (Ph) chromosome, which contains the BCR-ABL fusion gene (modified from 
Druker 2008). 
 
2.2.2 Three phases of CML 
 
Clinically, without effective treatment, CML exhibits three different phases: 
chronic phase or CML-CP (average duration 3 to 4 years), accelerated phase 
(CML-AP) (average duration 6 to 9 months) and finally the blast crisis (CML-
BC) (average duration 3 to 6 months) (Enright and McGlave 2000). 
 
As the disease progresses to a more advanced phase the myeloid cells 
progressively lose their ability to differentiate (Druker et al. 2001). Progression 
of CML is related to the acquisition of additional genetic alterations probably 
associated with genomic instability. This can be a consequence of BCR-ABL 
activation or it may even represent an ancestral stem cell defect preceding the 
Ph-chromosome translocation, as recent observations have suggested (Melo 
and Goldman 2007). With current TKI therapies (see Chapter 3.2) the average 
rate of progression is approximately 1% per year (Druker et al. 2006, Hocchaus 
et al. 2009, Kantarjian et al. 2010, Saglio et al. 2010, Kantarjian et al. 2011, 
Kantarjian et al. 2012, Larson et al. 2012).  
 
2.2.3 Symptoms and diagnosis 
Most patients are diagnosed in the chronic phase of CML (CML-CP), which is 
an early, indolent stage of the disease, when 40% of patients are asymptomatic 
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or may experience only mild CML-related symptoms (Kantarjian et al. 1993). 
Therefore many patients diagnosed in CML-CP may feel physically ‘well’ for 
extended periods (Lee 2000). The symptoms, which may occur during the 
chronic phase of CML are fatigue, weight loss, loss of appetite, abdominal 
fullness, splenomegaly, anemia and sweats (Savage et al. 1997, Faderl et al. 
1999). As CML advances to the accelerated phase and blast crisis, clinical 
symptoms become progressively worse (Cella et al. 2014). Patients with 
advanced forms of CML frequently report symptoms reflective of progressive 
bone marrow failure and splenomegaly, including weakness, fatigue, fevers, 
night sweats, weight loss, early satiety, and abdominal and bone pain (Faderl 
et al. 1999, Lee 2000, Hehlmann 2012). Diagnosis is fairly simple and consists 
of detection of the Ph chromosome abnormality or the Ph-related molecular 
BCR-ABL abnormalities (Jabbour and Kantarjian 2012). 
 
?????????????????
CML is a rare disease with an incidence of 1−2 cases per 100,000 individuals 
per year. It represents approximately 15% of adult leukemias (Hehlmann et al. 
2007, Hoffbrand et al. 2011, Association of the Nordic Cancer Registries 2013). 
The overall incidence is 1.6 times higher in men than in women (Ruutu et al. 
2000); this male predominance is found essentially in neonatal forms and in 
subjects aged 20 years and above.  
 
The European LeukemiaNet (ELN) designed a population-based registry in 
2007 to provide robust and updated information on the characteristics and 
epidemiology of CML (Hoffmann et al. 2015). All cases of newly diagnosed Ph-
positive, BCR-ABL CML that occurred in a sample of 92.5 million adults living 
in 20 European countries were registered over a median period of 39 months. 
Almost 95% of the CML patients (n=2904) were diagnosed in the chronic 
phase. The median age was 56 years. More than half (56%) of the patients had 
comorbidities, which were mainly cardiovascular (42%). The authors 
concluded that from a clinical point of view the results of most trials can be 
generalized to most countries. The incidences observed among European 
countries did not differ substantially. The estimated number of new CML cases 
per year in Europe is about 6,370 (Hoffmann et al. 2015). 
 
 
???????????????????
Approximately 50-60 new CML cases are diagnosed in Finland every year. At 
the time of diagnosis the patients’ average age is 55 years (Ruutu et al. 2000). 
The exact number of CML patients in Finland is not known, since there is no 
register covering all the patients. However, most of the CML patients are on 
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TKI medication, which is fully reimbursed by the social insurance system, 
which covers the entire population (Kaikkonen et al. 2012). Reimbursements 
are managed by the Social Insurance Institution Kela, which is supervised by 
the government. In 2015 the number of CML patients receiving 
reimbursement for TKI treatment was more than 520 (360 received imatinib, 
71 dasatinib, 90 nilotinib and <7 bosutinib and ponatinib; Figure 2) (Kela 
2016). Based on this we estimate there are approximately 550 CML patients in 
Finland in 2016. CML medication costs Kela 15 million euros a year (Kela 
2016). 
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??????????????????????
?
????????????????????????
The first pharmacotherapy reported to be active in CML was arsenic in 1865. 
Therapy remained palliative during most of the 1900s and included splenic 
irradiation, various cytostatic agents, of which busulfan was standard for 
almost three decades, and combination therapy (Melo and Goldman 2007). 
The intention of the treatment became curative with the introduction of stem 
cell transplantation in the 1970s (Goldman and Melo 2003). Interferon (IFN) 
in combination with hydroxyurea or low-dose cytarabine (ara-C) offered the 
prospect of prolonging survival, particularly in low-risk patients and in 
patients who achieve a cytogenetic remission (Hehlmann et al. 1994, Bonifazi 
et al. 2001).  
 
???? ????????????????????????????????????
The only cure for CML is allogeneic bone marrow transplantation (alloSCT), 
which is not always available or effective, and in itself represents a serious risk 
(Faderl et al. 1999). AlloSCT is the only currently available treatment that can 
render patients durably molecularly negative, but the associated procedural-
related morbidity and mortality are a major deterrent (Baccarani et al. 2013). 
 
?????????
Tyrosine kinases are important mediators of the signaling cascade, 
determining key roles in diverse biological processes like growth, 
differentiation, metabolism, and apoptosis in response to external and internal 
stimuli. Deregulation of protein kinase activity has been shown to play a 
central role in the pathogenesis of human cancers (Melo and Goldman 2007). 
 
CML became the first neoplasia in which the elucidation of the genotype led to 
a rationally designed therapy of the phenotype (Melo and Godman 2007). 
Imatinib mesylate was the first inhibitor, which targeted the pathogenetically 
relevant Bcr-Abl tyrosine kinase. The invention of imatinib and other TKIs 
(Figure 3) has induced remissions with almost complete disappearance of any 
signs and symptoms of CML (Melo and Goldman 2007). This therapy has 
triggered an intensive search for suitable targets in other cancers and has led 
to the development of numerous inhibitors of potential targets now being 
studied in preclinical and clinical trials worldwide (Melo and Goldman 2007).  
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      Imatinib (STI571)                                                             Dasatinib (BMS-354825)                                                          Nilotinib (AMN107)
  
  
                             
 
       Bosutinib (SKI-606)                                 Ponatinib (AP24534)?
 
   
 
Molecule First approval  Dose 
 
imatinib  2001  400-800 mg/day 
dasatinib 2006  100-140 mg/day 
nilotinib 2007  400-600 mg/day 
bosutinib 2012  400-600 mg/day 
ponatinib 2012  45 mg/ day 
?
????????????????
??????? ???????
Imatinib (Glivec®, STI571) was called a ‘magical bullet’ when it revolutionized 
the treatment of CML in 2001 (Lemonick and Park 2001). Imatinib was 
invented in the late 1990s by biochemist Nicholas Lyndon, and its use to treat 
CML was driven by oncologist Brian Druker (Iqbal and Iqbal 2014). Imatinib is 
an adenosine triphosphate analog that selectively inhibits the enhanced 
tyrosine kinase activity of the Bcr-Abl oncoprotein (Figure 4) and induces 
durable cytogenetic responses in the majority of patients with a relatively 
benign ADR profile (Glivec® SPC 2015). Imatinib blocks the ATP-binding site 
of the BCR-ABL tyrosine kinase with high affinity and high specificity (Druker 
2008). It has been found to be effective in the chronic and advanced phases of 
CML, as well as in blast crisis (Druker 2008).  
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CML CML 
ATP= adenosine triphosphate, ADP= adenosine diphosphate, P= phosphate 
?????????? ??????????????????????? ?????????????????????? ?????????????????????????????????
 
Although imatinib has been proven to be well tolerated and efficacious in the 
IRIS study (The International Randomized Study of Interferon and STI571) 
11% of patients discontinued the treatment due to an unsatisfactory 
therapeutic effect within five years (Druker et al. 2006). This may be attributed 
to the development of resistance in these patients. In most cases, resistance is 
associated with the emergence of clones expressing mutant forms of BCR-ABL, 
which exhibit decreased sensitivity to imatinib. Another 4% of patients in the 
IRIS trial had to discontinue treatment with imatinib because of ADRs (Druker 
et al. 2006).  
 
While 87% of new patients treated with imatinib in the chronic phase achieve 
complete cytogenetic remission, only 29% of patients treated with this drug in 
the accelerated phase obtain hematological remission (Hughes et al. 2003, 
O’Brien et al. 2003). At >5 years, progression-free survival (PFS) ranged 
between 83% and 94%, and overall survival (OS) ranged between 83% and 
97% (Druker et al. 2006). The number of patients still receiving initial imatinib 
treatment was reported at 63% to 79% after 3 to 5 years, and at 50% after 8 
years (Druker et al. 2006, Deininger et al. 2009). 
 
????????????????????????????????????????
Head-to head comparative clinical studies of TKI therapy in patients with CP- 
CML have shown that faster, deeper, and higher rates of cytogenetic and 
molecular responses are achievable with second- and third-generation TKIs vs. 
imatinib in the first-line setting (Kantarjian et al. 2012, Larson et al. 2012) and 
second-line setting following imatinib intolerance or resistance  (Rea et al. 
2012, Giles et al. 2013). 
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???????? ?????????
?
Dasatinib (Sprycel®) is a piperazinyl derivative (Figure 3) that targets many 
tyrosine kinases and has potent inhibitory activity against the active 
conformation of BCR-ABL and most mutated forms (Sprycel® SPC 2015). It is 
indicated for first- and second-line treatment of CML (Kantarjian et al. 2010, 
Sprycel® SPC 2015).  
 
The DASatinib versus Imatinib Study in treatment-naive CML patients 
(DASISION) study showed after 5 years follow-up, that 61% and 63% of 
patients randomized to receive dasatinib 100 mg once daily and imatinib 400 
mg once daily, remained on treatment (Cortes et al. 2014). Major molecular 
response (MMR) rates by 5 years were 76% with dasatinib vs. 64% with 
imatinib (p=0.002), and rates of MR4.5 were 42% and 33% with dasatinib and 
imatinib, respectively (p=0.025) 
In DASISION, 5-year rates of PFS were 85% with dasatinib vs. 86% with 
imatinib (Cortes et al. 2014). Similar rates of OS at 5 years were also observed 
with dasatinib (91%) vs. imatinib (90%) (Cortes et al. 2014). 
 
???????? ???????? 
 
Nilotinib (Tasigna®) is a strong inhibitor of the ABL tyrosine kinase activity of 
oncoprotein Bcr-Abl in cell lines and in primary Ph+ leukemia cells (Weisberg 
et al. 2005). It is active against the wild-type Bcr-Abl gene but also against 32 
of the 33 mutant forms of Bcr-Abl resistant to imatinib identified previously 
(Weisberg et al. 2005). 
 
In clinical trials nilotinib has demonstrated high efficacy and good tolerability 
in CML patients resistant to or intolerant to imatinib, and as first-line 
treatment (Kantarjian et al. 2007, le Coutre et al. 2008, Saglio et al. 2010).  In 
the 6-year follow-up of the Evaluating Nilotinib Efficacy and Safety in Clinical 
Trials–Newly Diagnosed Patients (ENESTnd) study patients treated with 
nilotinib 300 mg twice daily had significantly higher 6- year rate of MMR 
(77%) vs. imatinib (61%; p<0.0001) and MR4.5 (56%) vs imatinib (33%; 
p<0.0001) (Hughes et al. 2015). 
With 6 years’ follow-up in ENESTnd, similar rates of OS were observed in the 
nilotinib 300-mg and imatinib arms (92 % and 91%, respectively; p=0.709). 
OS rate in the nilotinib 400-mg arm was higher than in the imatinib arm after 
6 years’ follow-up (96% vs. 91%; p=0.0314) (Hughes et al. 2015). Follow-up of 
ENESTnd is ongoing and updates to survival end-points (PFS and OS) are 
awaited. 
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????????????????? 
Bosutinib (Bosulif®) is a second-generation TKI, which targets the BCR-ABL 
protein. Bosutinib is approved for the treatment of adult patients with CP-, AP-
, and BP- Ph+ CML previously treated with one or more TKIs and for whom 
imatinib, nilotinib and dasatinib are not considered appropriate treatment 
options (Bosulif® SPC 2015).   
 
 
??????????????????
Ponatinib (Iclusig®) is a third-generation TKI, which also targets the BCR-ABL 
protein. Ponatinib is indicated in adult patients with CP-, AP-, or BP-CML who 
are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or 
nilotinib and for whom subsequent treatment with imatinib is not clinically 
appropriate; or who have the T315I mutation (Iclusig® SPC 2015). 
 
 
???? ????????????????????????
European LeukemiaNet (ELN) proposed recommendations for the 
management of CML in 2006, 2009 and 2013 (Baccarani et al. 2013). The 
purpose of these guidelines is “to ensure the best possible duration and QoL 
for a given patient, and to avoid unnecessary complications and potentially 
achieve a cure, physicians and patients also must understand the proper use of 
available drugs, the significance of disease end points, the critical importance 
of monitoring, and, in some cases, the use of alloSCT as appropriate therapy” 
(Baccarani et al. 2013). ELN guidelines are used in CML practice in Finland. 
?
??????????????????????
During the era of TKIs treatment goals have become more complex and more 
ambitious (Baccarani et al. 2014). Treatment goals include preventing CML 
from progressing to the advanced phases, attaining a survival and QoL 
comparable to people without CML, as well as avoiding complications and 
deaths related to the TKI treatment.  
 
Treatment response in CML is measured on three different levels (Baccarani et 
al. 2013). The first goal is to achieve complete hematological remission (CHR) 
within three months of the baseline. Any patient who for any reason is not yet 
in CHR at 3 months must be considered a failure, mandating a change of 
treatment (Baccarani et al. 2014). The second goal is to achieve Ph negativity 
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or complete cytogenetic remission (CCyR) within 12 months of the baseline 
(Baccarani et al. 2013). To detect minimal residual disease, the most sensitive 
measure is to monitor the molecular response (MR) by measuring BCR-ABL 
expression (Kolibaba et al. 2013). The third goal is to achieve MMR within 18 
months of the baseline (Baccarani et al. 2009). MR and CCyR are associated 
with good long-term outcome in patients taking imatinib (Druker et al. 2006). 
Achieving CCyR or MMR significantly lowers the risk of disease progression. 
Regular monitoring of treatment response is recommended for early detection 
of a loss of response or signs of disease progression (Kolibaba et al. 2013). 
The response to TKI is the most important prognostic factor (Baccarani et al. 
2013). ELN does not recommend which TKI should be used but which 
response should be achieved, irrespective of the TKI used. The responses are 
defined as ‘optimal’ or ‘failure’. Optimal response is associated with the best 
long-term outcome – a lifespan comparable with that of the general 
population, indicating that there is no indication for a change in that 
treatment. Failure means that the patient should receive a different treatment 
to limit the risk of progression and death. Between optimal and failure there is 
an intermediate zone, which was previously referred to as ‘suboptimal’ and is 
now designated as a ‘warning. A warning implies that the characteristics of the 
disease and the response to treatment require more frequent monitoring to 
permit timely changes in therapy in case of treatment failure (Baccarani et al. 
2013). 
 
?????? ??????????????????????? ?????????? ??????????????
Understanding the sensitivity of the different methods used to measure BCR-
ABL is important to avoid over- and undertreatment (Baccarani et al. 2013). 
Three diagnostic methods are commercially available for the detection of BCR-
ABL: conventional karyotypic analyses, fluorescence in situ hybridization 
(FISH), and quantitative reverse transcriptase–polymerase chain reaction 
(qRT-PCR). Conventional cytogenetic analyses are performed on marrow 
aspirates, as the yield of cells in metaphase decreases significantly when 
peripheral blood myeloid progenitor cells are used (Baccarani et al. 2013). 
 
The most sensitive method to detect BCR-ABL is qRT-PCR, which is a 
molecular test. Through amplification of the BCR-ABL mRNA transcripts, 
qRT-PCR is capable of detecting the presence of BCR-ABL in 1 cell out of 1 
million normal cells, well below the detection level of conventional cytogenetic 
analysis or FISH (Hughes et al. 2006). Because of variations in standards for 
testing and reporting among laboratories, the International Scale was 
developed in 2009 to provide consistency in the interpretation of qRT-PCR 
results (Müller et al. 2009). Correlations between blood and marrow qRT-PCR 
results are excellent and therefore blood qRT-PCR is recommended for 
monitoring the treatment response in CML (Baccarani et al. 2013).  
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Recent findings show that healthcare providers tend to underestimate the 
intensity of symptoms felt by patients with advanced cancer (Laugsand et al. 
2010). Understanding the symptom burden from the patient’s perspective 
could be critical for making more informed treatment decisions, as all TKIs 
seem to provide excellent clinical outcomes (Hocchaus et al. 2009, Larson et 
al. 2012, Kantarjian et al. 2012, Chapters 3.2 and 3.3). This section describes 
the ADRs with imatinib, dasatinib and nilotinib. 
 
?????? ??????????????
Several ADRs related to TKI therapy in CML are common to all approved TKIs, 
including myelosuppression, rash, nausea, diarrhea, fatigue, and 
musculoskeletal pain/arthralgia/myalgia, albeit occurring at varying 
frequencies depending on the TKI (Table 1). Nevertheless, the TKIs also have 
different patterns of ADRs, and this should be considered when choosing 
among the available molecules (Pinilla-Ibarz et al. 2015). TKI dosages in 
second-line therapy may be higher than in first-line therapy, and patients on 
second-line therapy may have more advanced disease than those on first-line 
therapy. Both of these factors can have a detrimental effect upon the patients’ 
QoL (Cella et al. 2014). 
 
ADRs can be divided into three general categories. The first includes major, 
grade 3/4, ADRs that typically occur during the first phase of treatment, are 
manageable, but require temporary treatment discontinuation and dose 
reduction, and can lead to treatment discontinuation in about 10% of patients 
(Silver et al. 1999, Larson et al. 2012, Baccarani et al. 2013, Giles et al. 2013b, 
Mahon and Etienne 2014, Glivec SPC 2015, Sprycel SPC 2015, Tasigna SPC 
2015).   
 
The second category includes minor, grade 1/2, ADRs that begin early during 
treatment and can persist indefinitely and become chronic. They are also 
manageable and tolerable, but can negatively affect QoL and are a cause of 
decreased adherence (Pinilla-Ibarz et al. 2011, Efficace et al. 2013, Phillips et 
al. 2013, Efficace et al. 2014a, Glivec SPC 2015, Sprycel SPC 2015, Tasigna SPC 
2015). Many of these ADRs are common to all TKIs, with some differences in 
frequency and severity, so that several patients can benefit from changing the 
TKI.  
 
The third category includes late, so-called ‘off-target’ complications, which can 
affect the cardiovascular system, heart and blood vessels, the respiratory 
system, liver, pancreas, the immune defense, second malignancies, calcium, 
glucose, and lipid metabolism, etc. (Rasheed et al. 2009, Aichberger et al. 2011, 
Giles et al. 2013b, Kim et al. 2013). All TKIs can be toxic to the heart and 
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should be used with great caution in patients with heart failure. Nilotinib has 
been reported to be associated particularly with arterial pathology. Dasatinib 
has been reported to be associated particularly with pleura and lung 
complications. Overall, the long-term complications of second-generation TKIs 
are not yet fully understood and evaluable. Because these complications are a 
potential cause of morbidity and mortality, continued clinical monitoring of all 
patients is required (Pinilla-Ibarz et al. 2015). 
 
 
?????????????????????? ?????
??????????? ?????? ????
Pleural effusion is more commonly associated with dasatinib than with other 
TKIs (Quintás-Cardama et al. 2007). Pulmonary arterial hypertension (PAH) 
is observed primarily with dasatinib, most commonly in the second-line setting 
and in patients who previously experienced pleural effusion, suggesting a 
common etiology for these conditions (Quintás-Cardama et al. 2007, Rasheed 
et al. 2009, Irvine and Williams 2013). Prior to starting treatment with 
dasatinib, patients should be evaluated for PAH risk and for signs and 
symptoms of PAH during treatment (Sprycel SPC 2015). Dasatinib should be 
permanently discontinued if PAH develops on treatment (Sprycel SPC 2015).  
 
??????????????????????? ?????
Peripheral arterial occlusive disease (PAOD; defined as atherosclerotic and 
thrombotic events, excluding functional, embolic, or aneurysmal disorders, in 
the arteries of extremities) has been described in case reports and clinical 
studies of nilotinib (Quintás-Cardama et al. 2007, Larson et al. 2012). PAOD 
has also been reported with other TKIs. In a pooled analysis of 11 clinical 
studies of first- or second-line dasatinib (N=2,705), 0.2% of the patients were 
identified as having experienced PAOD or a related event (le Coutre et al. 
2013).  
 
The QT interval is an electrocardiographic measure of ventricular 
depolarization and repolarization (Fradley & Moslehi 2015). Prolongation of 
the QT interval is associated with an increased risk of the life-threatening 
rhythm torsades de pointes and sudden cardiac death. Although the QT 
interval is a relatively poor predictor for the development of torsades de 
pointes, it remains an important part of oncology drug development and 
surveillance (Fradley & Moslehi 2015). Corrected QT interval (QTc) 
prolongation (QTc ≥500 ms) is rare with TKI therapy in either the first- or 
second-line settings, even after years of treatment (Kantarjian et al. 2010, 
Larson et al. 2012, Giles et al. 2013a). As indicated in the Summary of Product 
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Characteristics (SPC) of nilotinib and dasatinib (Sprycel SPC 2015, Tasigna 
SPC 2015), use of TKI therapy in CML patients with known risk factors for QT 
prolongation is not recommended due to potential synergistic effects.  
 
???????? ???????????????????????? ?????
Gastrointestinal (GI)-related ADRs have been reported with all approved TKIs. 
In the first-line setting, GI-related ADRs were more frequent with imatinib 
than with either nilotinib (Saglio et al. 2010) or dasatinib (Kantarjian et al. 
2010).  
 
?????????????????????????????????
Abnormalities in metabolic parameters have also been reported with all TKIs. 
Grade 3/4 elevated glucose has been reported with nilotinib (Kantarjian et al. 
2011, Larson et al. 2012). Grade 3/4 hypophosphatemia occurred more 
frequently in the first-line setting with imatinib than with dasatinib (24% vs. 
7%). In the second-line setting, grade 3/4 hypophosphatemia was reported in 
17% of patients on second-line nilotinib (Kantarjian et al. 2011). In addition, 
chronic hypophosphatemia during TKI therapy may lead to disorders of bone 
mineralization, as observed in some patients on imatinib (Berman et al. 2006, 
Berman et al. 2013). The information on prescribing nilotinib recommends 
monthly monitoring of serum lipase levels and withholding therapy and 
adjusting dosage in cases of grade 3/4 elevated lipase or amylase (Tasigna SPC 
2015).  
?????? ??? ????????? ?????????? ??????????????? ?????? ?????? ?? ??? ?? ???????????? ?????? ????
?????????????????????????????????????????????????????????????????????????????????????????????
??????????????????? 
          
  Imatinib  Nilotinib Dasatinib 
  1st line 2nd line 1st line 2nd line 1st line 2nd line 
Frequent all-grade nonhematologic ADRs, %  
Fluid retention  60 69 19 6 25 30 
Nausea  50 63 11 25 10 18 
Muscle cramps  49 62 7 - - - 
Musculoskeletal 
pain  47 38 - - 11 19 
Diarrhea 45 48 8 12 19 27 
Rash/skin irritation 40 47 41 31 11 17 
Fatigue 39 48 11 21 9 24 
Abdominal pain 37 32 - - - 12 
Headache  37 36 14 18 13 33 
Arthralgia 31 40 - - - 12 
Nasopharyngitis  22 - - - - - 
Hemorrhage 21 30 3 <1 5 11 
Myalgia  21 20 10 11 6 13 
Vomiting  17 36 5 13 5 7 
Pyrexia  13 - - - - 5 
Weight increase 13 32 - - - - 
Constipation 9 - - 13 - 9 
Pruritus  7 9 15 26 - 10 
Grade 3 or 4 hematologic AEs, %
Neutropenia  17 36 12 31 24 35 
Thrombocytopenia  9 22 10 30 19 23 
Anemia 4 8 4 11 11 13 
Grade 3 or 4 biochemical abnormalities, %  
Elevated ALT/AST  5 3 4/1 4/3 <1/<1 - 
Elevated bilirubin  - - 4 7 1 - 
Elevated lipase  - - 9 18 - - 
Hyperglycemia  - - 7 12 - - 
Hypophosphatemia  - - - 17 7 - 
 
– = Not reported; ALT = alanine transaminase; AST = aspartate transaminase; URT = upper respiratory tract 
?
?
?
 34 
???? ??? ???????????????????
A standardized collection of health-related QoL data and other PROs has 
contributed to a better understanding of overall treatment effectiveness in 
patients with solid tumors (Phillips et al. 2013, Trask et al. 2013), but such 
evidence has been lacking in patients with leukemia (Aziz et al. 2011, Efficace 
et al. 2012b). PROs are defined by the FDA as “a measurement of any aspect of 
a patient’s health status that comes directly from the patient” (i.e., without the 
interpretation of the patient’s responses by a physician or anyone else) (FDA 
2009). Documenting QoL and the ADRs of CML treatments from the patients’ 
perspective is necessary to evaluate overall treatment effectiveness and the net 
clinical benefits of newer therapeutic strategies (Efficace et al. 2012b). More 
attention has been placed on understanding the impact of symptom burden on 
patient QoL.  
?
???????????????????????????? ??????????
There have been few validated QoL assessment instruments specific to 
leukemia (Cella et al. 2014). Recently, three leukemia- and CML-specific QoL 
instruments have been validated: the Functional Assessment of Cancer 
Therapy – Leukemia (FACT-Leu) (Trask et al. 2013), the M.D. Anderson 
Symptom Inventory-CML (MDASI-CML) (Williams et al. 2013) and the 
EORTC QLQ-CML24 (Efficace et al. 2014a). 
 
?????????????????
The Functional Assessment of Cancer Therapy – Leukemia (FACT-Leu) is a 
measure of leukemia-specific concerns in acute and chronic leukemias (Cella et 
al. 2012). Developed based on interviews with patients and healthcare 
providers and a literature search of symptoms or concerns associated with 
either acute or chronic leukemia, the scale comprises the 27-item FACT-G 
general QoL scale and a 17-item leukemia-specific subscale. The FACT-Leu 
includes 12 items on physical symptom concerns and five items on 
emotional/social concerns (Webster et al. 2002, Cella et al. 2012). 
 
???????? ?????????
The M.D. Anderson Symptom Inventory-CML (MDASI-CML) is a multi-
symptom instrument that assesses the severity of multiple symptoms and the 
impact of symptoms on daily functioning (Williams et al. 2013). The MDASI-
CML includes 13 core symptom items, seven CML-specific symptom items, and 
six items on interference with daily life.  
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????????????????? ??????????
The EORTC QLQ-CML24 was validated in 2013 (Efficace et al. 2013). Its 
development was based on a literature review of health-related QoL issues 
relevant to CML patients together with interviews with scores of CML patients 
and CML experts from Europe and Taiwan (Efficace et al. 2013).  
 
???????????????????????? ??????????????? ????????
As described in Chapter 2, CML is often diagnosed as asymptomatic in the 
chronic phase. It is known that even in the absence of disease symptoms 
negative emotional consequences can manifest (Cella et al. 2014). Efficace et 
al. found that CML patients younger than 59 years of age and women with 
CML both report more severe role limitations due to emotional problems than 
matched healthy controls (Efficace et al. 2011). It suggests that having CML 
can diminish overall QoL by affecting emotional health. 
 
Several studies have assessed QoL of patients with CML on TKI therapy (Hahn 
et al. 2003, Efficace et al. 2011, Efficace et al. 2012c, Phillips et al. 2013, Trask 
et al. 2013). The findings are variable. In an Italian GIMEMA study CML 
patients on long-term imatinib therapy overall reported QoL similar to that of 
the general population, but younger patients with CML were more negatively 
affected by the disease than older patients, and women more than men 
(Efficace et al. 2011).  
 
It has been found that baseline QoL and symptom burden measurements in 
patients with newly diagnosed CML-CP may have predictive value in terms of 
duration of treatment and the need for hospitalization (Cella et al. 2014). In 
some cases treatment with TKIs may even improve patient QoL. Patients in the 
IRIS study (Hahn et al. 2003) treated with imatinib reported significantly 
better QoL measures at each assessment than patients treated with IFN-α plus 
cytarabine.  
 
The rates of dose adjustment or discontinuation due to ADRs or treatment 
intolerance are higher than rates of disease progression: in the IRIS study the 
rates of disease progression in years 5, 6, and 8 were 0.5, 0, and 0.4% 
respectively. In those same years of follow-up, the rates of discontinuation due 
to ADRs or treatment intolerance were 5, 5, and 6% (Druker et al. 2006, 
Deininger et al. 2009, Hocchaus et al. 2009). Therefore the symptom burden 
associated with TKI therapy has a greater effect on the patients’ daily life than 
the symptom burden of the progressive disease (Cella et al. 2014). 
 
Studies published so far indicate that treatment with TKI therapy need not 
adversely affect QoL, especially if TKI-related toxicities are managed in such a 
way that patients can remain on therapy as directed, thereby maximizing the 
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likelihood of achieving better disease outcomes through significant delay of 
disease progression (Cella et al. 2014). ADRs are mostly mild to moderate in 
severity and generally consistent (i.e., predictable) over time and across lines 
of therapy. The number of TKIs currently approved increases the likelihood 
that patients found to be intolerant to one TKI can switch to another, more 
tolerable alternative. 
 
???? ?????????????????????????????????
In the last few years several studies have proved the feasibility and safety of 
imatinib discontinuation in CML. Criteria for discontinuation eligibility and 
for therapy resumption in cases of relapse have varied between different 
reports (Mahon et al. 2010, Ross et al. 2013, Rousselot et al. 2014, Mori et al. 
2015). The real percentage of patients diagnosed with CML who can safely 
discontinue imatinib in real life has only been estimated to be 9-15% (Branford 
et al. 2013, Horn et al. 2013). 
 
ELN recommends that a patient with CML who is responding optimally to TKI 
treatment should continue indefinitely at the standard recommended dose 
(Baccarani et al. 2013). The controlled discontinuations of imatinib have been 
attempted in some patients who were in sustained, deep MR (MR4.5 or better) 
(Mahon et al. 2010, Ross et al. 2013, Rousselot et al. 2014). Approximately 
40% of them maintained the same degree of response during a follow-up of 1 
to 4 years. Almost all of those who had a molecular recurrence regained the 
same level of deep response when treatment with imatinib was resumed. These 
data provide a proof-of-principle for the hypothesis that TKI treatment can be 
discontinued safely, even though some BCR-ABL cells always remain 
detectable (Sobrinho-Simoes et al. 2011, Chomel et al. 2011, Chu et al. 2011).  
 
However, ELN states that data are still insufficient to make recommendations 
about discontinuing treatment outside of well-designed, prospective, 
controlled studies (Baccarani et al. 2013). TKI treatment discontinuation may 
be considered in individual patients, also outside studies, if proper, high 
quality, and certified monitoring can be ensured at monthly intervals. This is 
especially relevant to those fertile women who may have achieved an optimal 
response, because conception and pregnancy are contraindicated during TKI 
treatment. In these patients, when the optimal response has been stable for at 
least two years, TKI treatment discontinuation with or without the use of 
rIFNa can be considered after informed consent and with very frequent 
molecular monitoring (Baccarani et al. 2013). 
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???????????????????
?
There is limited data available in the literature on patient journey, and even 
less on the cancer patient’s journey. Cancer is a long-term disease with several 
stages, and it would therefore be important to understand the different phases 
the patient goes through during the course of the disease, which can be called 
‘patient journey’. The first and only study on the CML patient journey was 
published in 2013 (Guilhot et al. 2013).  
 
 
????????????????????????????? ???
 
Hall et al. published a cancer experience map in 2015 (Figure 5). The map 
demonstrates the complexity of the cancer experience while capturing the 
common points of change and transition throughout the journey. Based on 
direct quotes from cancer patients, the map identifies behavioral factors at 
different experience stages.  
 
A multidisciplinary team (a medical writer, an oncology specialist, and two 
user experience researchers) at a health information company tasked with 
addressing this issue created a representational model they call the ‘cancer 
experience map’. Informed by actual patient quotes, the map shows common 
overall themes for cancer patients, concerns at key treatment points, strategies 
for patient engagement, and targeted behavioral goals (Hall et al. 2015).  
 
 
?????????????????????????????
The only CML patient-related model found from the literature is that 
published by Guilhot et al. (2013; Figure 6). They identified five common 
stages experienced by patients with CML and suggested several 
recommendations for healthcare professionals on the management of patients 
through their disease journey. By providing support, education, and 
reassurance, healthcare professionals can help patients as they move through 
the early stages of crisis and hope. When patients are in the adaptation and 
new-normal stages, healthcare professionals can help patients achieve and 
maintain a new normality by setting expectations for the risks/benefits of long-
term drug therapy and disease monitoring and by continuing to support 
patient adherence (Guilhot et al. 2013). 
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?????? ????????????????????? ??????????????????????
?
Guilhot et al. showed that patients with CML progress through five distinct 
stages: crisis, hope, adaptation, new normalcy, and uncertainty. The ability to 
cope with these stages is affected by the degree of knowledge about the disease, 
comfort level with the physician, and optimism about the success of treatment 
(Guilhot et al. 2013). 
?
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??????? ??? ???? ??????????? ????????????????? ??????? ?????? ??????????? ???? ?????????? ???? ???????
???????????????????????????????????????????????????????????????????????????????????????????
???? ????????? ????????? ???? ?????? ???????? ???? ???????? ??????? ??????????? ???? ??????? ??? ????
??????????????????????????????????????????????????????????????????????????? ??????????????????????
?
?
???????????????????????????????????????????
There are five university hospitals and 15 central hospitals treating CML in 
Finland. CML is usually diagnosed by a hematologist or internist. After TKI 
initiation patient treatment responses are monitored in accordance with ELN 
Guidelines (Baccarani et al. 2013). In one hospital, patients do not meet 
healthcare professionals after treatment initiation and attend only for 
laboratory test monitoring if the treatment response is according to the 
guidelines. Patients are informed of the laboratory results based on each 
hospital’s protocol 1) by mail 2) by phone or 3) during a doctor’s appointment. 
?
?
?????????????????????????????????? ?????????? ??????????
????????? ???????
As described in Chapter 2, the treatments for CML have developed over the 
decades. Nevertheless, there is little data available in the literature showing 
how the treatment of patients with CML is coordinated.  
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Holloway et al. (2012) established a team in the USA that included a 
hematologist, a physician assistant, and a nurse, allworking closely with a 
social worker, a pharmacist, and a research coordinator to assist patients 
throughout their journey with CML. The patient and the referring community 
oncologist were incorporated into this team. This coordinated team care 
approach took advantage of each member’s specific skills to provide patients 
with education about CML, encourage patients’ strong involvement in 
tracking, monitoring results and response to therapy, and to support patients 
with issues that arise throughout the journey with the disease. A low rate of 
non-adherence with clinic visits (3%) was an indirect measure of the impact of 
this approach on adherence.  
In an era of readily accessible information, empowering patients to participate 
in their care requires reliable educational materials and a good understanding 
of monitoring the results. In the US model, the hematologist, the first team 
member the patient meets on the initial visit, is an experienced leukemia 
specialist with expertise in all CML treatment modalities. In this model, 
patients are empowered through education to better understand their illness 
and are engaged as active team members in monitoring their responses to 
therapy (Holloway et al. 2012). 
A multidisciplinary approach in cancer has been shown to improve patients’ 
adherence with treatment appointments and the treatment regimen (Boxer et 
al. 2011), reduce anxiety about their overall care, enhance quality of life, and 
improve the outcomes of certain malignancies (Gany et al. 2010, Du et al. 
2011). In this US team model, the patient’s understanding of the results of 
response monitoring is used to tailor additional education at each subsequent 
clinic visit. Through frequent communication between the leukemia specialist 
and the referring physician, knowledge about the disease and monitoring is 
relayed beyond the academic medical center to community providers 
(Holloway et al. 2012). 
Exposing the patient at each clinic visit to professional team members who 
deliver a consistent message throughout the course of the disease has 
improved relationships between patients and the team, and in some cases has 
improved patient adherence with clinic visits. The authors conclude that this 
kind of approach can help to improve overall management of CML by 
providing patient education, improved alliances with the healthcare team, and 
a good understanding of response monitoring (Holloway et al. 2012). 
?
?
?
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?? ?????????
?
The use of patient-administered treatments is a growing trend in oncology 
(Weingart et al. 2008). A patient’s ability to adhere to the requirements of 
their medication regime is central to the successful delivery of self-
administered anticancer treatments. Research on medication adherence has 
been growing rapidly over the past 50 years, as chronic diseases have become 
more prevalent and treatment more dependent on patient self-management 
(Sabaté 2003). Data suggest that the difference in health outcomes between 
high and low adherence patients is 26%, and that the adherence–outcome 
relationship varies with the regimens, measurements, and diseases studied 
(Sabaté 2003). 
This chapter describes the concept of adherence both in general and from the 
point of view of cancer and CML. 
 
???? ???????????????????????
According to the World Health Organization, adherence is defined as ‘‘the 
extent to which a person’s behavior (including medication-taking) corresponds 
with agreed recommendations from the health care provider’’ (Sabaté 2003). It 
includes the initiation of the treatment, implementation of the prescribed 
regime, and discontinuation of the pharmacotherapy (Vrijens et al. 2012). The 
WHO has cited the problem of non-adherence with oral medications as the 
single most modifiable factor influencing treatment outcomes – having an 
even greater impact than improvements in specific medical treatments (Sabaté 
2003).   
‘Compliance’, a term also often used, has a different meaning (Sabaté 2003, 
Lehane and McCarthy 2009). Compliance describes “the extent to which the 
patients’ behavior (including medication-taking) coincides with medical or 
healthcare advice” (Sackett et al. 1978), though its meaning has become more 
negative regarding a patient’s behavior, since it implies passivity (Vermeire et 
al. 2001). In this thesis, therefore, only the term ‘adherence’ will be used.  
 
???? ???????????????????????????
There are different definitions for non-adherence (See also Chapter 5.6.1 and 
Table 3). In the UK CML study patients were classified as non-adherent if they 
had shown an adherence rate ≤90% measured using microelectronic 
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monitoring systems (MEMS) (Marin et al. 2010). The 90% cut-off was chosen 
because >90% was the level of adherence that best predicted clinical responses 
in their previous study (Marin et al. 2010). Investigators have also assessed 
adherence through self-reporting during the interviews by specifically asking 
patients, “It is common that patients at times miss a few doses, for a whole 
range of reasons. Thinking just of the past 7 days have you missed any doses?” 
If a patient answered ‘yes’ to this question it was taken as an indication that 
he/she had experienced problems with adherence (Haynes et al. 2002).  
If non-adherence is defined as any deviation from the recommended treatment 
protocol, the problem of non-adherence becomes even more significant. 
Reports suggest that the proportion of patients adhering to the therapeutic 
regimen exactly as prescribed is as low as 19.8% (Almeida et al. 2010). 
 
?????? ?????????????????????????????????????????????????????????
‘Intentional’ non-adherence is defined as the patient deciding to alter or 
discontinue the treatment, and ‘unintentional’ non-adherence as the patient 
intending to take the medication as prescribed, but being unable to do so 
(Horne et al. 2002, Nunes et al. 2009). Intentional non-adherence can happen 
even when patients are fully aware of the risks and consequences of not taking 
their medications as prescribed. For instance, one factor that could contribute 
to intentional adherence is ADRs experienced by the patient. Unintentional 
non-adherence occurs when a patient is willing to follow the agreed treatment 
but fails to do so due to factors beyond their control. A patient can, for 
example, forget to take the prescribed medication, misunderstand the 
instructions, be unable to pay for the treatment, or have difficulties in 
administering the medication; it may also be due to a prescribing error 
(Eliasson et al. 2011, Gadkari and McHorney 2012).   
 
???? ?????????? ??????????????????
Adherence represents a range of behaviors from taking all medication as 
prescribed to an occasionally skipped dose and taking few or no doses at all 
(Osterberg and Blaschke 2005). Different tools have been used to evaluate and 
assess patients’ adherence to medication, and there is no ‘‘gold standard’’ 
measure of medication adherence. 
 
The methods used to monitor medication adherence are either direct or 
indirect and include self-reporting, frequency of repeat prescriptions, pill 
counts, drug plasma levels, and various microelectronic monitoring systems 
(Sabaté 2003, Osterberg and Blaschke 2005, Ruddy et al. 2009; Table 2). Self-
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reporting is probably the most frequently used method, but it is often biased 
because many patients overestimate their medication adherence (Partridge et 
al. 2002). 
 
Monitoring of drug or metabolite concentrations may be one of the more 
accurate ways to measure adherence, but this method has its own challenges in 
that it is only applicable to certain drugs, and it may not account for individual 
variation in the metabolism of the drug (Lam and Fresco 2015). Concentration 
monitoring may not be practical or financially feasible for most patients 
(Partridge et al. 2002). Additionally, the data for many anticancer medications 
are insufficient to recommend routine therapeutic drug monitoring in clinical 
practice.  
Although several different approaches have been used to assess medication 
adherence, the issue still remains as to what cut-off should be used to define 
adequate adherence (Nieuwlaat et al. 2014). The literature is conflicting 
regarding what percentage of doses taken should be used to define adherence, 
and many studies use a range of 80–95% (Partridge et al. 2002, Osterberg and 
Blaschke 2005). Little evidence is available to support these values, and the 
percentage desired may vary depending on the medication prescribed and the 
corresponding disease state (McCue et al. 2014).  
 
 
????????? ?????????? ?????????????????????????????????????????? ???????????????????
? ? ? ? ?
Method   Pro   Con 
Drug or metabolite 
concentrations 
 Objective; high level accuracy  Not applicable to all 
medications; does not account 
for pharmacogenomics; 
expensive 
Microelectronic monitoring  Precise; quantitative  Expensive; mostly used in 
clinical trials; does not track 
ingestion of medication 
Pill counts  Objective; quantitative; easy to 
perform 
 Easily altered by patient; does 
not account for adherence to 
schedule 
Prescription refill history  Objective; easy to obtain data  Does not account for adherence 
to schedule 
Self-reporting   Simple; inexpensive; useful in 
clinical setting 
  Often overestimated and subject 
to patient bias 
?
?
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???????????????????????????????????
Standardized, self-reported questionnaires have frequently been used because 
they are low in both cost and time expenditure. Early studies found that the 
self-report method underestimated non-adherence when compared with pill 
counts or biological assays (Saini et al. 2009, Moore and Brandt 2010). 
However, subsequent research suggests that the self-report method may 
provide a reasonably accurate estimate of adherence (Grunfeld et al. 2005, 
Hershman et al. 2010). Such questionnaires, validated by more objective 
measures, may also be useful in identifying patients who may benefit from 
intervention. 
 
 
???????? ??????????????
Among structured, self-reported scales, a four-item self-reported questionnaire 
to assess medication adherence was developed by Morisky et al. (1986). 
Although the four-item scale has shown poor psychometric properties, it is one 
of the most widely used self-reported measures of medication adherence 
(Shalansky et al. 2004).  It has been used in two published CML adherence 
studies (Efficace et al. 2012, de Almeida et al. 2013).  
 
An eight-item self-reported scale called the Morisky Medication Adherence 
Scale (MMAS) was developed by Morisky et al. in 2008 (Appendix 1). MMAS is 
a structured questionnaire validated to estimate adherence to treatment and is 
widely used in chronic diseases (Morisky et al. 2008). The 8-item scale 
consists of seven questions with ‘yes’ or ‘no’ alternatives and one item (the last 
one) with a 5-point Likert scale. MMAS evaluates items addressing the 
circumstances surrounding adherence behavior. Each item measures a specific 
medication-taking behavior and not a determinant of adherence behavior. 
MMAS scores can range from 0 to 8 and have been classified into three levels 
of adherence: high adherence (score 8), medium adherence (score 6 to 7.75) 
and low adherence (score <6) (Morisky et al. 2008). 
 
 
??????????????????????????????????????????????????
Daouphars et al. (2013) have recently developed a self-assessment 
questionnaire consisting of 10 questions to identify patients who were not 
adhering to their cancer treatment. Each answer was worth 1 point, resulting in 
a possible maximum score of 10. The questionnaire was validated in patients 
receiving imatinib, using an objective adherence evaluation: a patient’s score 
on the self-assessment questionnaire was correlated with prescription refills, 
expressed as a medication possession ratio. A score of less than 8 was 
associated with a positive predictive value of 0.83 to have a medication 
possession ratio below 90%. Using this questionnaire, half of the patients 
receiving imatinib would be identified as being non-adherent (sensitivity 0.5). 
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Few adherent patients would be falsely identified as non-adherent, as the 
questionnaire’s specificity was 0.97 (Daouphars et al. 2013). 
 
?????? ?????
The Medication Event Monitoring system (MEMS) consists of electronic 
detection of package entry by incorporating a microcircuit into pharmaceutical 
packages of various designs, which detects, time-stamps, and stores the 
maneuvers needed to remove a drug dose (Vrijens and Urquhart 2014). This 
automatic compilation of times of medication intake (dosing history) provides 
a thorough characterization of medication adherence, with clear distinctions 
between initiation, implementation and discontinuation (Vrijens and Urquhart 
2014). However, opening the medication package does not necessarily 
correlate with administration of the medication and can be manipulated by the 
patient. This system is also expensive and therefore may not be a feasible 
option within the community setting (Ruddy et al. 2005). 
 
MEMS is an indirect method of estimating when the drug is administered and 
how much, but it has been shown to give a good prediction of drug 
concentration in plasma (Vrijens and Urquhart 2014). Electronic monitoring 
of package entry is the current gold standard for automatically compiling drug 
dosing in trial settings (Vrijens and Urquhart 2014). It has been used in more 
than 700 peer-reviewed publications (Lam and Fresco 2015). 
 
Alili et al. (2016) found in their recent scoping review, that when MEMS was 
compared to non-electronic methods, the median adherence per method was 
overestimated by 17% (range: -21%, 75%) for self-report, 8% (-25%,50%) for 
pill count and 6% (-15%,50%) for rating.  
 
??????????????????
Pill count is an indirect, objective measure that counts the number of dosage 
units that have been taken between two scheduled appointments or clinic 
visits. This number would then be compared with the total number of units 
received by the patient to calculate the adherence ratio (Farmer 1999, Vik et al. 
2004). The low cost and simplicity of this method contribute to its popularity.  
Adherence underestimation occurs frequently, since this method simply uses 
the dispensed date as the denominator of the equation without considering the 
chance of having surplus medication (Lam and Fresco 2015). It is common for 
patients with chronic conditions, in particular, to replenish their medication 
before it runs out (Vik et al. 2004). The cut-off value to differentiate between 
adherence and non-adherence, in this case, is generated arbitrarily (Farmer 
1999).  
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Even though pill count is based on a similar assumption to MEMS, i.e. that 
removal of the dosage unit is equivalent to taking the medication, pill count 
does not generate a medication-taking pattern like MEMS does (Lam and 
Fresco 2015). Removing the correct number of dosage units from the container 
does not necessarily mean the patient follows the dosing regime consistently 
(van Onzenoort et al. 2010). Besides pill count’s inability to characterize the 
adherence pattern, it is also unable to identify its causes (Farmer 1999).  
Pill count has shown higher accuracy compared to other subjective methods, 
but MEMS has replaced pill count as a reference standard for validating other 
adherence measures in the 1990’s (Farmer 1999).  
?
????????????????????????????
It has been documented in the literature that physicians are inaccurate 
estimators of adherence and are ‘‘no better than chance’’ at judging which 
patients are adherent and which are not (Wagner et al. 2001, Zeller et al. 
2008). When estimating the degree of adherence for any particular patient, 
physicians have been shown to be accurate only 10–40% of the time, for both 
medication and other treatments (Turner et al. 2001, Parker et al. 2007, 
Morton et al. 2008). Improving non-adherence detection by physicians has the 
potential to directly increase patients’ treatment adherence and improve 
patients’ health outcomes (Phillips et al. 2011). 
Phillips et al. found several factors related to physicians’ adherence 
predictions, including physicians’ perceptions of patient agreement regarding 
treatment. The degree to which physicians discussed treatment specifics with 
the patient moderated agreement perception accuracy but not adherence 
prediction accuracy.  
Little is presented in the literature about how physicians estimate their CML 
patients’ adherence to TKI therapies. In the Belgian ADAGIO study, physician-
investigators were asked to estimate the percentages of patients adhering to 
imatinib treatment in the first month after diagnosis and after one year (Noens 
et al. 2009). The physicians in that study believed that on average 92.8% of 
patients were imatinib adherent in the first month after diagnosis and 87.4% 
after one year of treatment.  
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???? ????????????????????
The adherence rates to oral anticancer therapies vary greatly; for example, a 
review of six studies investigating adherence to oral anticancer treatments in 
adults reported non-adherence rates between 0% and 83% (Partridge et al. 
2002). This variation in reported non-adherence rates can be partly explained 
by differences in methods and measurements and by definitions of non-
adherence. The average non-adherence rate to oral anticancer treatments has 
been estimated as 21% (DiMatteo 2004).  
Patients with breast cancer are the most studied population with regard to how 
well they adhere to oral cancer therapy. A recent systematic review of the use 
of adjuvant hormonal therapy in clinical practice showed that adherence over 
periods longer than four years ranged from 41% to 72%, while the rate of 
discontinuation ranged from 31% to 73%, measured after five years of therapy 
(Murphy et al. 2012). Adherence to other oral therapies used in the treatment 
of breast cancer has been reported to be higher than that measured with 
hormonal therapies (Mayer et al. 2009, Partridge et al. 2010, Ruddy et al. 
2012). It is unclear whether this variation is due to differences in methodology, 
treatment plan, breast cancer status, or a combination of these factors.  
 
???? ????????????????
?????? ??????????????????????
The definitions and measures of medication adherence have varied between 
studies assessing adherence of CML patients to TKIs (Table 3). Some studies 
report adherence as a percentage rate (Darkow et al. 2007, Noens et al. 2009, 
Ibrahim et al. 2010, Marin et al. 2010a, Ibrahim et al. 2011, Koren-Michowitz 
et al. 2012, Marin et al. 2010b), others report a mean adherence rate (Darkow 
et al. 2007, Noens et al. 2009, Almeida et al. 2010, Casamartina et al. 2010, 
Marin et al. 2010a, Marin et al. 2010b, Ibrahim et al. 2011), some report the 
score from an adherence measure (Noens et al. 2009; Wu et al. 2010a, Wu et 
al. 2010b, Wu et al. 2011, Guérin et al. 2012, Jönsson et al. 2012), while others 
classified patients into levels of adherence, such as low, medium and high 
(Darkow et al. 2007, Lee et al. 2009, Almeida et al. 2010, Guerin et al. 2010, 
Wu et al. 2010a, Wu et al. 2011, Efficace et al. 2012a, Jönsson et al. 2012). 
Variation in definitions of adherence makes it difficult to gain an accurate 
estimate of the rate of medication adherence in patients with CML. Most 
studies report the level of non-adherent behavior in a proportion of CML 
patients. Of those studies providing data on the number of patients who were 
fully or 100% adherent (Almeida et al. 2010, Guerin et al. 2010, Wu et al. 2011, 
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Efficace et al. 2012a), very few patients met these criteria, with rates ranging 
from 20% (Almeida et al. 2010) to 53% (Guilhot et al. 2010). When the mean 
adherence rates were provided, patients’ level of adherence ranged from 76% 
(Feng et al. 2006) to 98% (Casamartina et al. 2010, Ibrahim et al. 2010, Marin 
et al. 2010a, Marin et al. 2010b, Koren-Michowitz et al. 2012). 
?
?????????????????????????????????????????????? ????????
Medication adherence is a multi-factorial phenomenon (Ruddy et al. 2009, 
Gater et al. 2012, Jabbour et al. 2012) influenced by numerous patient, disease, 
treatment, healthcare system and social factors (Ruddy et al. 2009, Gater et al. 
2012, Jabbour et al. 2012; Figure 7).  
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????????????? ?????????? ??????????????????????????????????????????????????????
Measurement tool Adherence calculation  Adherence definition  
1) Monitoring systems  
 
MEMS Dose taken according to the MEMS reading 
expressed as a percentage of the dose 
prescribed during the total duration of the 
study  
*Definition of adherence according to MEMS 
not provided 
  *Non-adherence defined as ≤90% as 
measured by MEMS (90% cut-off chosen as it 
was the level of adherence that best predicted 
clinical responses in a previous clinical 
study)  
2) Manual monitoring    
a) Pill count  Percentage of imatinib taken to imatinib 
prescribed 
*Definition of adherence not provided  
b) Adherence with scheduled appointments  Ratio of appointments scheduled to 
appointments kept  
*Definition of adherence not provided 
 Dose interruptions of more than one-week 
due to non-attendance at scheduled 
appointments  
 
3) Medication possession    
a) Medication possession ratio (MPR)  Total days’ dose of TKI divided by number of 
days in the observation time  
*Definition of adherence according to MPR 
not provided 
  *Low MPR (non-adherence) defined as <85% 
(85% threshold chosen as it is midpoint of 
previous thresholds in cancer research)  
  *Good (≥90%); medium (70–89.9%); poor 
(<70%) 
  *Low (<65%); medium (65–95%); high (95–
100%)  
b) Treatment possession ratio  [total dose of treatment obtained at 
pharmacy]/[total dose of treatment 
prescribed at hospital during the same 
period]  
*Definition of adherence not provided  
c) Daily average consumption   [Total mgs dispensed]/[Total days supply]  *Definition of adherence not provided 
d) Treatment discontinuation  Continuous days of non-treatment  *Gap > 20 days due to non-adherence  
  *Gap ≥ 30 days  
4) Medication claims    
a) Proportion of days covered   [Days of supply for claims of the index 
drug]/[number of calendar days in the study 
period (i.e. up to 6 months after the index 
date)]  
*Definition of adherence not provided  
5) Clinician reported outcome  (CRO)   
a) Basel Assessment of Adherence Scale with 
immunosuppressive medication 
4-Question clinical interview guide, used 
with patients and carers  
*Non-adherence: positive answer to any 
question  
b) Visual analogue scale (VAS)  Rating of patient adherence on 10 cm VAS 
scale (physician, patient and carer rating)  
*Definition of adherence not provided  
6) Patient reported outcome (PRO)    
a) Qualitative patient interviews  Patient self-report question: “It is common 
that patients at times miss a few doses, for a 
whole range of reasons. Thinking of the past 
7 days have you missed any doses?”  
*If a patient answered ‘yes’ it was taken as an 
indication that patient had problems with 
adherence. 
b) Visual analogue scale (VAS)  Rating of patient adherence on 10 cm VAS 
scale (physician, patient and carer rating)  
‘Intentional’ non-adherence: patient deciding 
to alter or discontinue the treatment. 
  ‘Unintentional’ non-adherence: patient 
intending to take medication as prescribed, 
but unable to do so *Definition of adherence 
not provided  
7) Combined CRO/PRO assessment   
a) CML-Q  Specific questions asking about compliance 
to medications (How often miss medications)  
*‘True-compliance’ (patient-perceived and 
physician-perceived compliant) or ‘non-
compliance’ (reported non-complaint by 
patient, physician or both)  
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In order to better understand the complex factors that influence patients’ 
adherence to TKIs, Gater et al. (2012) have developed a conceptual model of 
adherence to peroral TKIs for the treatment of CML (Figure 8). 
This model consists of four different levels: 1) predisposing factors or baseline 
characteristics of the individual patient, the disease, potential treatment and 
the prescribing physician, 2) factors influencing the relationship between the 
patient and prescribing physician, and patients’ interactions with the 
healthcare system during initial treatment decision-making and treatment 
maintenance, 3) patients’ beliefs and experiences regarding the treatment and 
incorporating the treatment into their daily lives, and 4)  treatment outcomes 
and perceived benefits of adherence to therapy (Gater et al. 2012).  
????????????????????? ????????????????????????????????????????????????????????????? ???????????
??????? ?????????????????????????????????????????????????????????????????????????????????????????
???????????????????????????????????????????????????????????? ?????????????????????????????????
?????????????????????????????????????????????????????????????????????????????????????????? ????
???????????????????????????????? ???????????????????????????????????????????????????????????????
???????????????????????????????????????????????? ???????????????????????????????? ???????????
????????????????????? 
Disease Characteristics
+/- Age +/- High prescription burden
+/- Gender -Time since diagnosis 
-Quality of Life/functional status -Temporary other illness
-Time from diagnosis to prescription 
fill -Concomitant disease
-Risk of pregnancy
- Unintentional overdose
- Unable to obtain prescription from pharmacy
- Forgetting to take medication
+ Routines and forward planning
+ Monitored dosing boxes and prompts
+ Family / Carer Support
+ Achievement of major / complete + Quality of Life / functional status - Overall direct costs
cytogenetic response - Outpatient and urgent care visits - Inpatient costs
+ Achievement of major / complete - Inpatient hospital stays and length of stay - Outpatient costs
molecular response +/- CML treatment drug costs
- Non-CML treatment drug costs
+ Second generation TKIs
+ Favourable physical properties 
(size, shape, colour, taste)-Cancer complexity or complications
Persistence
(alcohol consumption, dining out, travel, holidays)
Patient Knowledge and Beliefs
+Perception of consequences of non-adherence
+ Disease understanding
+ Treatment understanding
+ Faith in physician and treatment option
Treatment Characteristics
-Dose
-Treatment duration
-Treatment ADRs
-Financial cost to patient
Lifestyle factors 
Unintentional factors
Clinical Patient Economic
- Social situation 
Physician Interaction
+ Communication with healthcare provider
Treatment Satisfaction      
- Treatment side effects
+ Number of active patients with
CML seen in the past year
+ Median duration of first visit with 
newly diagnosed CML patient
+ Median duration of follow-up visits
+ Years of professional experience
Benefits of Adherence
+ Physician explanation of treatment effects / need for adherence
Patient Charasterictics
Adherence
?
Patient Interaction with Physician and Healthcare Systems
Prediposing factors
Behavioural Management
Physician Characteristics
+ Physician awareness of patient non-adherence
+ Interpretation of clinical response in relation to adherence
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????????????????????????????????
Three patient characteristics have been found to impact on hematological 
cancer patients’ medication adherence: 1) forgetfulness, 2) patient education, 
knowledge and understanding, and 3) patients’ physical and emotional feelings 
(Hall et al. 2016). Forgetting to take the medication as prescribed was the most 
common reason for patient non-adherence (Eliasson et al. 2011).  
CML patients’ education, knowledge and understanding influence medication 
adherence behavior. Patients with a secondary or higher level of education 
report higher levels of adherence than those with a lower level of education 
(Noens et al. 2009). Patients who reported inadequate medical knowledge (Wu 
et al. 2011) were more likely to be non-adherent. Patients who reported better 
knowledge of the impact of non-adherence on their disease and treatment were 
more likely to be adherent (Abraham et al. 2008, Noens et al. 2009). Patients 
who had a tendency to become complacent after long periods of disease control 
were less likely to adhere to their prescribed medications (Wu et al. 2011).  
Patients’ physical and emotional feelings influence adherence. Higher levels of 
perceived QoL have been found to be associated with higher levels of 
medication non-adherence (Noens et al. 2009). On the other hand, higher 
levels of patient-perceived self-efficacy in relation to long-term medication 
behavior were found to be associated with better medication adherence (Noens 
et al. 2009). Reducing the impact that the drug had on the patient’s life was 
identified as a reason why patients did not adhere (Wu et al. 2011).  
The findings are inconsistent if age is related to higher levels of adherence in 
CML patients. Some studies identify older age as being associated with non-
adherence (Abraham et al. 2008, Noens et al. 2009), adherence as being 
associated with increasing age (Feng et al. 2006), or finding younger age to be 
related to non-adherence (Marin et al. 2010a; StCharles et al. 2009). Gender 
has not been consistently found to be associated with medication adherence 
rates. In two studies females reported higher rates of non-adherence (Darkow 
et al., 2007) or lower levels of adherence (Feng et al. 2006) and one study 
identified male gender as being related to higher rates of non-adherence 
(Noens et al. 2009).  
?
???????? ???????????????????????????????????? 
Time since diagnosis was found to be associated with CML patients’ level of 
medication adherence in two publications (Noens et al. 2009, Abraham et al. 
2008). Patients who were further from diagnosis had higher rates of 
medication non-adherence (Noens et al. 2009, Abraham et al. 2008). It is 
reported that adherence to oral TKIs decreases over time (Almeida et al. 2010). 
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Longer duration of treatment has been associated with higher levels of non-
adherence (Noens et al. 2009, Abraham et al. 2008, Almeida et al. 2010).  
Higher rates of treatment ADRs have been associated with higher rates of non-
adherence (Marin et al. 2010a). Patients reduced, stopped or altered their 
medication without medical advice in an attempt to avoid treatment ADRs and 
to make them feel physically better (Eliasson et al. 2011, Jacobsen et al. 2011).  
Participation in a clinical trial may increase adherence (Almeida et al. 2010, de 
Almeida et al. 2010). Taking medication independent of meals has been 
associated with higher rates of non-adherence (Marin et al. 2010a).  
The physical characteristics of oral anticancer medications (e.g. size, shape, 
color, taste) and defining aspects of treatment regimens (e.g. dose and 
treatment duration) all influence adherence to TKIs for the treatment of CML 
(Gater et al. 2012). The role of medication type is still unclear. It has been 
associated with non-adherence (Almeida et al. 2010, Guérin et al. 2012, 
Oliveria et al. 2011, Wu et al. 2010b), with some studies reporting lower 
adherence in patients treated with dasatinib compared to those treated with 
nilotinib (Guérin et al. 2012, Wu et al. 2010b). Nilotinib use has been found to 
be related to higher rates of medication adherence compared to imatinib and 
dasatinib (Almeida et al. 2010). Another study found that patients treated with 
nilotinib reported poorer rates of adherence compared to dasatinib users 
(Oliveria et al. 2011).  
There are different reports on the effect of dose on adherence in CML patients. 
In six studies (Noens et al. 2009, Marin et al. 2010a, Wu et al. 2010a, Darkow 
et al. 2007, StCharles et al. 2009) a higher dose or an increase in dose was 
found to be associated with higher levels of non-adherence. One study found a 
lower dosage of medication to be associated with medication adherence (Yood 
et al. 2012); while one study reported that a starting dosage of ≤400 mg of 
imatinib was related to non-adherence (StCharles et al. 2009). 
The data available on the effect of concomitant medications also vary. 
Adherence to TKIs has been found to decrease with an increase in the number 
of concomitant medications prescribed to patients (Feng et al. 2006, Noens et 
al. 2009, StCharles et al. 2009). On the other hand, one study found that a 
higher concomitant drug burden was related to higher rates of medication 
adherence (Efficace et al. 2012).  
 
??????????????????????????????????????????
Patients with CML living alone (Noens et al. 2009, Abraham et al. 2008) had 
higher levels of non-adherence, while higher levels of social support were 
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associated with higher adherence (Efficace et al. 2012). Low socioeconomic 
status has been associated with non-adherence (StCharles et al. 2009).  
?
???????? ?????????????????????????????????
The type of healthcare services accessed by patients with CML has been found 
to be associated with their level of medication adherence. Patients who made 
use of individual counseling about medication adherence or attended an 
institution with established protocols on managing patient adherence had 
higher adherence rates to their pharmacological treatment (Guilhot et al. 
2010).  
Some healthcare provider characteristics have been associated with patients’ 
level of adherence. A higher number of healthcare providers’ years of 
professional experience, higher number of active patients seen in the last year, 
median duration of first visit with a newly diagnosed patient, practising in a 
university or teaching hospital, and holding a specialization in hematology 
(Noens et al. 2009) have all been associated with higher medication adherence. 
On the other hand, shorter median duration of follow-up visits has been 
associated with increased non-adherence (Noens et al. 2009).  
Physician and patient communication has been identified as affecting patients’ 
level of adherence (Eliasson et al. 2011, Wu et al. 2011). Miscommunication 
between patients and physicians (Wu et al. 2011), patients who were unable to 
access appropriate medical guidance (Wu et al. 2011) and patients who felt 
they were reassured by their physicians that their non-adherence would not 
have a detrimental effect on their treatment response (Eliasson et al. 2011, Wu 
et al. 2011) have reported higher levels of medication non-adherence.  
 
????????????????????????????? ?????????????????????
Hematological cancers are increasingly being treated with self-administered 
medications, which may have long and complex treatment regimens (Agrawal 
et al. 2010). Strategies to improve medication adherence for patients with 
hematological cancers is critical given the evidence that there is a negative 
association between medication non-adherence and lower perceived disease 
severity (DiMatteo et al. 2007). Medication adherence has been found to 
decrease with long-term medication use (Gater et al. 2012), which may be 
problematic for many hematological cancers that require long-term treatment.   
Adherence is affected by both behavioral and system barriers (Touchette and 
Shapiro 2008). Several intervention strategies, such as informational, 
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behavioral and combined strategies, have been explored to address adherence 
in chronic conditions. Informational interventions have been described as 
“cognitive strategies designed to educate and motivate patients by 
instructional means” (Touchette and Shapiro 2008). Behavioral interventions 
are designed to influence behavior through shaping, reminding, or rewarding 
desired behaviors (Kripalani et al. 2007). Combined interventions have 
features of both these (Touchette & Shapiro 2008). It has also been found that 
complex programs utilizing multiple interventions delivered over a longer 
period of time are more likely to achieve better outcomes (Peterson et al. 1984, 
Bailey et al. 1990, Piette et al. 2000, Farber and Oliveria 2004, Kripalani et al. 
2007).  
For most patients, non-adherence to pharmacotherapy is due to several factors 
present either at the same time or sequentially (D’Amato 2008, Doucette et al. 
2012), and any single type of intervention is unlikely to be successful in 
improving adherence (Osterberg and Blaschke 2005, D’Amato 2008). Possible 
interventions range from simple to complex and can utilize the skills of a 
multidisciplinary team that includes pharmacists, nurses, physicians, and 
other healthcare professionals. Using multiple interventions and different 
methods over time may be the most successful approach (Touchette and 
Shapiro 2008). 
Few published studies have addressed adherence improvement techniques in 
patients with cancer. The methods described for the general population have 
therefore been extrapolated for this group of patients (McCue et al. 2014).  
?
?????? ???????????????????????????
The most important aspect of medication adherence is creating and 
maintaining a good relationship between the healthcare professional and the 
patient and family, in which open communication is encouraged (Boyle and 
Bubalo 2007, Hansen 2012). The healthcare professional should discuss with 
the patient and family the expected outcomes of the therapy and the potential 
ADRs while modifying the information for the individual patient (McCue et al. 
2014). The message should be kept simple and complete enough to meet the 
patient’s needs. Some patients need to be reassured that oral cancer 
treatments are effective, but that results will not be seen immediately 
(D’Amato 2008). Patients should be informed about the need for good 
medication adherence and the possible consequences of poor adherence 
(Eliasson et al. 2011).  
?
?
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????????????????????????
Patients and their caregivers have significant educational needs at the start of 
oral anticancer treatments (D’Amato 2008). It is recommended that whenever 
possible, the patient’s family members, a friend, or a caregiver should be 
present to receive the education with the patient (Boyle and Bubalo 2007, 
D’Amato 2008). All information should be delivered in verbal and written 
form (D’Amato 2008). The physicians can deliver the education, but this is 
more commonly handled by nurses or pharmacists (Schneider et al. 2011). 
Extensive oral chemotherapy education should contain the following 
information: drug and indication, dose, dosing schedule, start date, 
administration, what to do if doses are missed, possible food and drug 
interactions, treatment-related ADRs and their management, clinic contact 
information, and safe handling instructions for the medication (McCue et al. 
2014). The importance of medication adherence should always be 
communicated, together with the potential consequences of non-adherence. 
Patients should be advised not to stop or change the medication dose without 
consulting with their hematology healthcare team (McCue et al. 2014).  
Unfortunately, in many cases patients with cancer may not internalize much of 
the content in the initial teaching session (McCue et al. 2014). They may be 
overwhelmed, especially if they have received the diagnosis at the same visit. 
The information might need to be repeated either at a subsequent visit or over 
the phone (McCue et al. 2014).  
Patient education initiatives, including a combination of face-to-face contact 
and interactive technologies or videos, have proved to be the most effective 
(Gysels et al. 2004). Verbal instructions should always be accompanied by 
written material (McCue et al. 2014). Written information should be 
appropriate in terms of healthcare literacy level amount. It is easy for 
healthcare professionals to forget how strange and complex medical jargon can 
be. Some patients might read the information well but have difficulty 
translating it into action (McCue et al. 2014).  
If the medication is to be given more than once a day, patients should be asked 
to tell the healthcare professional what times of the day they will take it. If the 
medication is to be taken on an empty stomach, patients should state when 
they usually eat and when, in relation to mealtimes, they will take the 
medication. Planning these aspects in advance will help ensure patients’ 
medication adherence (McCue et al. 2014). In an era of readily available and 
easily accessible information, patients can easily become confused and 
anxious, effectively suffering from ‘information overload’ (Kim et al. 2007).  
?
?
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???????? ????????????? ?????????????? ???
The medication regimen should be made as simple as possible in order to 
improve adherence (D’Amato 2008). The dosing schedule of anticancer 
treatment is often not modifiable because many medications are administered 
just once daily. The total complexity of the medication regimen depends on all 
the medications a person is taking, not just the cancer treatment. A complete 
medication history should be recorded at each evaluation. Every effort should 
be made to decrease the total number of medications, making sure that each is 
useful and appropriate in the context of cancer treatment. Creating a 
medication schedule that requires fewer administration times per day will 
improve adherence (McCue et al. 2014) 
 
?????????????????????
Forgetting to take medication is the most common reason cited by patients for 
non-adherence, and a variety of reminder tools may be of assistance (Boyle 
and Bubalo 2007, Doucette et al. 2012). Patients should be taught to take their 
medications with other routines in their daily lives, such as meals or brushing 
their teeth (Boyle and Bubalo 2007, Eliasson et al. 2011) and storing the 
medication in a visible and frequently used place (Eliasson et al. 2011). 
Patients may find pill dispensers to be helpful in remembering to take their 
medications and to verify that the dose has been taken (Osterberg and Blascke 
2005, Boyle and Bubalo 2007, D’Amato 2008, Schneider et al. 2011). 
New technological adherence aids have been invented during recent years in 
order to improve patients’ adherence. There are alarms available on watches or 
smartphones, text or phone reminders, and electronic pill dispensers that 
announce when a dose is due (Boyle and Bubalo 2007, D’Amato 2008, 
Schneider et al. 2011). Many recent studies have shown positive results with 
text messages as sole adherence aid (Lester et al. 2010, Castano et al. 2012, 
Foreman et al. 2012, Wald et al. 2014, Khonsari et al. 2015). 
Written medication schedules, diaries, and charts may help some patients to 
stay organized and adherent (D’Amato 2008, Touchette et al. 2008, Schneider 
et al. 2011). The most appropriate tool is the one the patient prefers and will 
use consistently (McCue et al. 2014). 
?
???????????????????? ???????? ????
The key to improving medication adherence is to provide close follow-up 
contact and support (Osterberg and Blascke 2005, Boyle and Bubalo 2007, 
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D’Amato 2008, Schneider et al. 2011). Many patients will have further 
questions about their medication only after they have begun to take it. Patients 
may have ADRs that may adversely affect their adherence (see Chapter 3.5 and 
5.6.2.2). Follow-up contact usually happens by phone between regularly 
scheduled provider visits for ease and convenience. The first contact with the 
patient should happen within 1–2 weeks of starting the medication, both to 
provide support and to address early concerns. Follow-up contacts may 
become less frequent as patients have been on their medication for a longer 
time and are tolerating it well (McCue et al. 2014). 
Managing toxicity from oral chemotherapy agents is crucial to helping patients 
stay on their medication (D’Amato 2008). Early ADRs may discourage patients 
from continuing their treatment, and patients do not always call for assistance 
when they need it. Patients should be encouraged to report ADRs and their 
severity so that management measures can be taken (McCue et al. 2014). 
At each follow-up, patients should be asked if they are adhering to their 
medication regimen (Ruddy et al. 2009). This may be as simple as asking them 
how many doses they have missed in the last 1–2 weeks and why it happened. 
The adherence rate might stay high because patients know that the healthcare 
team will ask if they are taking their medications (McCue et al. 2014).  
For patients with difficult adherence issues, guided counseling could be 
beneficial to explore more fully the reasons for non-adherence (see Chapter 
5.7.6) (McCue et al. 2014). 
 
?????? ?????????????????
Motivational interviewing or guided counseling helps to explore the patient’s 
own motivation and skills for change (Possidente et al. 2005). This method 
focuses on enabling patients to discover and strengthen their own motivation 
for change. These skills can be learned by any healthcare provider and can help 
patients focus on their own goals for themselves (McCue et al. 2014). Guided 
counseling requires the provider to listen nonjudgmentally to the patient, 
avoid prescribing ‘fixes’ for the problem, and to use open-ended questions. It 
also points out how the patient’s goals and actions might be incongruent. 
Motivational interviewing skills can help facilitate open communication with 
patients facing any illness and treatment (McCue et al. 2014). 
?
?????????????????????????????????
The Cochrane systematic review assessed the effects of interventions intended 
to enhance patient adherence to prescribed medications for medical 
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conditions, on both medication adherence and clinical outcomes (Haynes et al. 
2008). Nieuwlaat et al. (2014) updated searches of The Cochrane Library in 
2013 with no language restriction.  
This systematic review included randomized control trials (RCTs) of 
interventions to improve adherence with prescribed medications, measuring 
both medication adherence and clinical outcome, with at least 80% follow-up 
of each group studied and, for long-term treatments, at least six months 
follow-up for studies with positive findings at earlier time points. The update 
included 109 RCTs published since their previous update in January 2007 
(Haynes et al. 2008) bringing the total number of RCTs to 182. Studies were 
heterogeneous for patients, medical problems, treatment regimens, adherence 
interventions, and adherence and clinical outcome measurements, and most 
had a high risk of bias.  
Of all 182 RCTs, 17 had the lowest risk of bias for study design features and 
their primary clinical outcome, 11 from the present update and six from the 
previous update. The RCTs at lowest risk of bias generally involved complex 
interventions with multiple components, trying to overcome barriers to 
adherence by means of tailored ongoing support from allied health 
professionals such as pharmacists, who often delivered intense education, 
counseling (including motivational interviewing or cognitive behavioral 
therapy by professionals) or daily treatment support (or both), and sometimes 
additional support from family or peers. Only five of these RCTs reported 
improvements in both adherence and clinical outcomes, and no common 
intervention characteristics were apparent. Even the most effective 
interventions did not lead to large improvements in adherence or clinical 
outcomes (Nieuwlaat et al. 2014). 
The authors concluded that the effects were inconsistent from study to study, 
and only a minority of lowest risk of bias RCTs improved both adherence and 
clinical outcomes. Current methods of improving medication adherence for 
chronic health problems are mostly complex and not very effective, so that the 
full benefits of treatment cannot be realized (Nieuwlaat et al. 2014). Research 
in this field needs advances, including improved design of feasible long-term 
interventions, objective adherence measures, and sufficient study power to 
detect improvements in patient-important clinical outcomes (Nieuwlaat et al. 
2014). 
?
???????????????????????? ?????? ?????????????????????????????????????
????
Even though high medication adherence is crucial for clinical response in TKI 
treatment, little evidence exists to show whether interventions influence the 
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adherence of patients with CML. Only one previous study providing such 
evidence has been published (Moon et al. 2012). This was a cross-sectional 
study of Korean patients with chronic CML prescribed imatinib. The patients 
were assigned either to a counseling program or to receive standard treatment. 
The counseling program consisted of phone consultations with a nurse and 
daily text message reminders to take the medication. The control group 
received written information from their medical team. ‘Overall compliance’ 
was defined as the product of ‘persistency’ (percent of the number of days of 
imatinib prescribed versus 1 year) and ‘dose compliance’ (milligrams of 
imatinib that were actually taken versus milligrams that should have been 
taken). The overall compliance to imatinib of those who participated in the 
counseling program was 93% after the 36-month follow-up period compared 
to 76% for the standard treatment patients (p<0.001) (Moon et al. 2012). 
?
?
?
?
?
?
?
?
?
?
?
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????????????? ???? ???? ????????? ??? ????
???????????????????????????????? 
CML is a clonal disease of the hematopoietic stem cells in the bone marrow, 
which leads to a marked proliferation of granulocytes in the blood (Goldman 
and Melo 2003). In almost all patients (95%), CML is characterized by a 
specific chromosome translocation known as the Philadelphia chromosome 
(Nowell et al. 1960, Rowley JD et al. 1973, Sawyers 1999). Most patients are 
diagnosed in the chronic phase of CML, which is an early, indolent stage of the 
disease, when 40% of patients are asymptomatic or may experience only mild 
CML-related symptoms (Kantarjian et al. 1993). Introduction of the first TKI, 
imatinib, caused a dramatic change in the management of CML more than ten 
years ago (Stone 2004). The prognosis of the patients improved and treatment 
moved from hospitals to patients’ homes. There are approximately 550 CML 
patients in Finland in 2016. CML medication costs the Social Insurance 
Institution Kela 15 million euros a year (Kela 2016). 
The response to TKI is the most important prognostic factor (Baccarani et al. 
2013). Several ADRs related to TKI therapy in CML are common to all 
approved TKIs, including myelosuppression, rash, nausea, diarrhea, fatigue, 
and musculoskeletal pain/arthralgia/myalgia, albeit occurring at varying 
frequencies depending on the TKI. Nevertheless, TKIs also have different 
patterns of ADRs, and this should be considered when choosing among the 
available molecules (Pinilla-Ibarz et al. 2015).  
 
Documenting QoL and the ADRs of CML treatments from the patients’ 
perspective is necessary to evaluate overall treatment effectiveness and the net 
clinical benefits of newer therapeutic strategies (Efficace et al. 2012). In the 
last few years several studies have proved the feasibility and safety of imatinib 
discontinuation in CML. Forty to 60% of patients who achieved a stable 
undetectable BCR-ABL transcript (UMD; [MR4 or MR4.5] and discontinued 
imatinib, experienced long-term TFR (Mahon et al. 2010, Ross et al. 2013, 
Rousselot et al. 2014).  
 
Guilhot et al. (2013) showed that patients with CML progress through five 
distinct stages: crisis, hope, adaptation, new normalcy, and uncertainty, and 
the ability to cope with these stages is affected by the degree of knowledge 
about the disease, comfort level with the physician, and optimism about the 
success of treatment (Guilhot et al. 2013). 
A patient’s ability to adhere to the requirements of their medication regime is 
central to the successful delivery of self-administered anticancer treatments. 
Adherence represents a range of behaviors from taking all medication as 
prescribed to an occasionally skipped dose and taking few or no doses at all 
(Osterberg and Blaschke 2005). Different tools have been used to evaluate and 
 61 
assess patients’ adherence to medication, and there is no ‘gold standard’ 
measure of medication adherence.  
 
According to some studies, CML patients’ level of adherence ranged from 76% 
(Feng et al. 2006) to 98% (Casamartina et al. 2010, Ibrahim et al. 2010, Marin 
et al. 2010a, Marin et al. 2010b, Koren-Michowitz et al. 2012). It has been 
documented in the literature that physicians are inaccurate estimators of 
adherence and are ‘no better than chance’ at judging which patients are 
adherent and which are not (Wagner et al. 2001, Zeller et al. 2008). Little is 
known in the literature about how the treating physicians estimate their CML 
patients’ adherence to TKI therapies.   
The factors influencing CML patients’ adherence to TKIs are complex: patient 
characteristics, disease and treatment, the patient’s social characteristics, and 
healthcare system related matters. 
Few published studies have addressed adherence improvement techniques in 
patients with cancer (McCue et al. 2014). Even though high adherence is 
crucial for clinical response in TKI treatment, little evidence exists to show 
whether interventions influence adherence of patients with CML. Only one 
previous study providing such evidence has been published (Moon et al. 2012). 
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?? ? ????????????????
The overall objectives of this study were to explore adherence to TKIs of 
patients with CML in Finland from different angles: 1) the patient’s own 
perspective, 2) the physician’s perspective, 3) treatment-related ADRs and 4) 
QoL, and to create a model to improve patients’ adherence to TKIs. 
The specific study aims are the following:  
 
1) To evaluate adherence to TKI medication (imatinib, dasatinib, 
nilotinib) in adult CML patients who had been on TKI medication for 
at least the last six months before the assessment in Finland (I). 
 
 
2)  To compare the adherence reported by the CML patients with that 
assessed by their physicians (experienced vs. observed adherence) 
(I). 
 
 
3) To evaluate ADRs experienced by CML patients during peroral TKI 
treatment and the correlation of ADR symptoms with medication 
adherence and perceived QoL (II, III).  
 
4) To investigate low-adherent CML patients’ experiences of their 
patient journey and identify reasons for not taking their TKI 
medication as prescribed (I, III). 
 
5) To evaluate the influence of a tailored patient education program 
combining nurse-conducted counseling and interactive information 
technologies (IT) on adherence of patients with CML using TKIs after 
a nine-month intervention period (IV).  
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??????????????? ???????
?????????????????????????????
This study applied both qualitative and quantitative methods (Table 4).  ?
????????? ?????????????????????????????????????? 
?????? ???????? ?????????????????????? ????????? 
??? ???? ?????
?? 
86 personal, open-ended theme 
interviews in 2012-2014.  
For Study IV also a second interview 
after 9 month follow-up (n=68) 
Interviews of 
patients with CML 
Qualitative analysis: Abductive content analysis 
 
Quantitative analysis: demographic data collected at the 
beginning of the interview; Descriptive statistics: frequencies, 
percentages, means, and medians  
II: Spearman’s rho test 
III: Pearson’s chi-square  (gender, employment status: 
working/not working, and usually the same doctor), Fisher’s 
exact test (marital status: in relationship/not in relationship, 
number of TKI doses, and use of pill dispenser). Mann 
Whitney U test (age, age at diagnosis, time from diagnosis, 
number of doctor’s visits during the last 12 months, number of 
comorbidities and number of other medications). 
IV: Fisher’s exact test (MMAS class, MMAS questions, gender, 
education, TKI medication, treatment line, knowledge of the 
disease and treatment at baseline) between the groups. The 
Mann-Whitney U test (age, duration of the disease, MMAS 
score, number of co-morbidities, number of other 
medications) between the groups. The Wilcoxon signed rank 
test to compare changes within the groups. 
??? ???? ?????
??? 
 Self-reported adherence 
questionnaire 
Morisky 8-Item 
Scale (MMAS) 
Quantitative analysis:  
II: Spearman’s rho test 
IV: Fisher’s exact test (MMAS class, MMAS questions) 
between the groups. The Mann-Whitney U test (MMAS score) 
between the groups. The Wilcoxon signed rank test to 
compare changes within the groups. 
Descriptive statistics,  
?? Questionnaire  ADR and QoL questionnaire 
Quantitative analysis:  
II: Spearman’s rho test 
 
?? Questionnaire 
Physician’s 
assessment on 
adherence 
questionnaire 
Quantitative analysis:  
Descriptive statistics; frequencies, percentages, means, and 
medians 
???????????
 
Questionnaire 
 
Knowledge of the 
disease and 
treatment 
questionnaire 
Quantitative analysis:  
Descriptive statistics; frequencies, percentages, means, and 
medians 
?
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Study IV was a randomized multicenter intervention study adhering to the 
CONSORT statement (Figure 9). Patients were randomized by the main 
investigator (MK) into either an intervention group with additional adherence 
support or a control group receiving standard treatment (Figure 10). There was 
a stratified randomization design based on sex and age.  
?
?
??????????????????????????????????????????? ???????????????????????????????????????????
?????????????
The study period was from June 2012 to September 2013 (I, II, III) and from 
June 2012 to August 2014 (IV). All Finnish secondary and tertiary care 
hospitals (n=20) treating CML patients were invited to participate in the study. 
Eight of them agreed to participate (Helsinki University Central Hospital, 
Tampere University Hospital, Turku University Hospital, Oulu University 
Hospital, Satakunta Central Hospital, Mikkeli Central Hospital, South Carelia 
Central Hospital and Central Hospital of Länsi-Pohja). The patients were 
recruited for this study by physicians treating CML patients in these hospitals. 
All patients recruited gave their written informed consent. The study protocol 
was approved by the ethics committees of the hospitals concerned. 
Study IV was powered to detect a 20% difference in adherence as estimated 
using a two-sample T-test. In order to give 80% power (5% two-sided 
significance) in adherence rates at nine months, predicated on 95% for the 
intervention group versus 75% for the control group, a sample size of 25 
patients was required in each group (treatment vs. control, 50 patients in 
total).
?
?
?
?
?
?
?
?
?
?
?
?
?
?
?
? ?
Assessed for eligibility (n= 120) 
)
Excluded (n= 34) 
♦???Not meeting inclusion criteria (n= 26) 
♦???Declined to participate (n= 8) 
 
Analyzed (n=35) 
♦?Excluded from analysis (n= 0)?
Lost to follow-up (not reached) (n=1) 
Discontinued intervention (stopped TKI 
treatment, disease progression) (n=7) 
Allocated to interventiona (n= 43) 
♦?Received allocated intervention (n= 43)?
♦?Did not receive allocated intervention (n=0) 
Lost to follow-up (not reached) (n=10) 
Discontinued control group (n=0) 
Allocated to standard treatmentb (control 
group, n= 43) 
♦?Received standard care (n= 43)?
♦?Did not receive standard care  (n= 0)  
Analyzed  (n= 33) 
♦?Excluded from analysis (n=0)?
???????????
Analysis 
Follow-Up 
Randomized (n=86) 
Enrollment 
aIntervention: Educational video, personal patient counseling, SMS reminders, information booklet, website 
bStandard care: Normal laboratory tests and visits based on hospital’s procedure. No additional education session or 
adherence tools provided. 
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???? ???????
??????????????????????????????????
???????? ?????????????????????????????????????
Patient-reported adherence (experienced adherence) was evaluated in Studies 
I-IV using Morisky’s 8-Item Medication Adherence Scale (MMAS) (Morisky et 
al. 2008, Chapter 5.3.1.1, Appendix 1). As this was the first time MMAS has 
been used in a Finnish-speaking patient group, the instrument was translated 
into Finnish using a method that assures its face validity (Sartorius and 
Kuyken 1994). MMAS was first translated from English into Finnish. The 
Finnish version was then independently translated by another translator back 
into English. If significant differences were apparent, they were discussed until 
equivalence between both versions was achieved. 
The 8 MMAS questions were asked verbally at the beginning of the personal 
interviews with the patients (see Chapter 8.3.2). In Study IV adherence was 
assessed at baseline and at nine months by the main investigator (MK).  
Items 2, 3 and 6 in MMAS were considered in the analyses as intentional non-
adherence (“People sometimes miss taking their medications for reasons other 
than forgetting. Thinking over the past two weeks, were there any days when 
you did not take your Chronic myelogenous leukemia medication(s)?”; “Have 
you ever cut back or stopped taking your medication(s) without telling your 
doctor, because you felt worse when you took it?”; “When you feel like your 
Chronic myelogenous leukemia is under control, do you sometimes stop taking 
your medication(s)?”). Item 1 was considered in the analyses as unintentional 
non-adherence (“Do you sometimes forget to take your Chronic myelogenous 
leukemia medication(s)?”). 
 
???????? ??????????????????
 
For Study I, in addition to experienced adherence, the treating physicians were 
asked to give their subjective opinion on patients’ adherence (observed 
adherence). If the patient did not have a long-term doctor relationship, the 
questions were put to the physician who had treated the patient during his/her 
last appointment in the hospital. The physician’s opinion was rated to 
represent 1) ‘high adherence’ if the physician thought the patient was taking 
the medication as prescribed (selection of item 1), 2) ‘medium adherence’ if 
there might be some problems with medication-taking (selection of item 2), 
and 3) ‘low adherence’ if the doctor thought the patient had severe problems 
and was non-adherent (selection of item 3). Experienced adherence was 
compared with observed adherence using the three-level rating system (high-
medium-low) described above.  
 66 
?????????????????????????
 
All the patients participated in the in-person interview with the main 
investigator (MK) (Studies I-IV). MMAS questions were asked at the beginning 
of the interview (Studies I-IV). A semi-structured interview method with pre-
defined key topics and themes was used. The interviews were conducted using 
a flexible structure, which allowed conversational, two-way communication 
between interviewer and interviewee (Mason 2004). Interviews were 
audiotaped and transcribed verbatim by a professional transcriber.  
The interview themes followed the idea of the patient’s journey with CML from 
the time before diagnosis to the study point. The themes covered patients’ own 
perceptions of the following phases of the patient journey: getting the CML 
diagnosis, information gathering, satisfaction with the treatment and 
healthcare system, medication adherence, behavioral aspects, knowledge of the 
disease and its treatment, patient-reported ADRs and sociodemographic 
factors (social network and support) (Study III). 
Each patient’s demographic data were collected during the interview as 
follows: gender, age, marital status, education, occupation, employment status, 
time from CML diagnosis, time from diagnosis to the start of TKI treatment, 
TKI medication, dose, line, duration of usage, co-morbidities, other 
medications, medication review, dosing time, number of medical doctor (MD) 
visits during the last 12 months, MD visits during the first year after the start of 
TKI, nurse contacts in 12 months, nurse contacts during the first year after the 
start of TKI, phone contacts in the last 12 months, and days in 
hospital/hospitalization for any reasons after CML diagnosis.  
The patient’s knowledge of the disease and TKI treatment was evaluated by 
asking five questions. Every correct answer scored one point, i.e., the total 
score ranged from 0 to 5 points.   
At the time of the interview, the therapeutic response to TKI was 
assessed according to the patient's individual follow-up schedule. 
 
??????????????????????????????????????? ????
 
Patient-reported ADRs were assessed during the interview using a structured 
questionnaire (Studies II and III). The questionnaire consisted of a list of 19 
CML and TKI treatment-specific symptoms, and six items assessing the 
symptoms’ interference with the patient’s daily life (QoL). Patients were asked 
about the ADRs they experienced at the time of the study using a list of 
symptoms collected from the most common ADRs caused by TKIs in phase 
three studies. The interviewer followed the standardized symptom inventory 
questionnaire and every symptom was investigated by asking, “After the start 
of the TKI treatment have you suffered or are you currently suffering from the 
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(mentioned) symptom”. The following alternatives were given: 1) not 
applicable, 2) has suffered before, but not at the moment (these answers were 
not included in the analysis), or 3) yes, I am currently suffering from this 
symptom (included in the analysis). The number of patient-reported ADRs was 
taken as a ‘symptom score’, each reported symptom yielding one score (score 
range 0-1).   
 
?????????????????????? ???
 
The patient interview also included six structured questions assessing 
functional impairment associated with TKI treatment (QoL) (Study II). QoL 
was assessed as a negative influence of patient-reported ADRs on six items: 
mood, general health, enjoyment of life, walking, relationships and work in 
general. Each item scored one point (i.e. the patient answered ‘yes’), leading to 
a maximum score of six. This was considered as a measure of QoL. If the 
patient did not report any negative influence on his/her daily QoL, the score 
was ‘0’. The correlation between ‘QoL score’ and ‘symptom score’ was 
measured. 
 
????????????????????????????????????????
In Study IV the patients were interviewed nine months after starting the 
intervention. The intervention group patients were also asked to give their 
opinion of the educational material, adherence aids and face-to-face 
counseling by using a structured questionnaire at the end of the interview.  
 
???????????????????
 
The intervention in Study IV was based on tailored patient education 
combining nurse-conducted face-to-face counseling and interactive 
information technologies. The education was provided by hematology nurses 
trained to deliver the intervention. The nurses’ knowledge of CML and 
adherence to medication was assessed. All were trained in adherence and 
patient counseling to be able to support patients with the adherence aids and 
material used in this study (Table 5). The main training session lasted one 
hour. There were also additional rehearsals before the first patient counseling 
session.  
Each patient in the intervention group attended a one-on-one tailored 
education session with a hematology nurse. The session repeated the same 
content in three different ways: audiovisual, verbal and written. At the 
beginning of the session, each patient watched a 5-minute video via an iPad at  
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Adherence 
aid 
Mode of 
delivery 
Key content Purpose Special 
features 
Video  
(5 minutes) 
Audiovisual, can 
be repeated by 
the patient at 
home 
Knowledge of the 
disease, 
explaining the 
reasons for the 
importance of 
medication 
taking 
To increase 
understanding of 
the disease, 
treatment goals, 
importance of 
medication taking 
and psychosocial 
factors in an 
audiovisual story 
form  
Video entitled 
“Treat yourself 
correctly” - 
Story told by a 
doctor and a 
patient 
Patient 
counseling 
(30 
minutes) 
Verbal, 
interactive 
Knowledge of the 
disease, goals for 
treatment, 
understanding 
lab tests, 
importance of 
medication 
taking, side 
effect 
management, 
psychosocial 
support 
See above, 
encourage the 
patient in self-
management in an 
interactive setting 
 
Information 
booklet 
Visual, 
repeatable at 
home 
Knowledge of the 
disease, goals for 
treatment, 
importance of 
medication 
taking, side 
effect 
management, 
psychosocial 
support 
Increase 
understanding  of 
the disease, 
treatment goals, 
importance of 
medication taking 
and psychosocial 
factors in written 
form including 
figures/pictures 
Ability to keep 
a symptom and 
medication 
diary. 15 pages 
long with an 
appendix 
including a 
medication 
card and a side 
effect diary.  
Website Visual, IT, 
repeatable  
 Repetition of the 
verbal and visual 
versions 
 
Text 
messaging 
IT, repeatable Reminder of 
medication 
taking time 
To remind 
patients to take 
the medication on 
time 
Ability to 
manage 
features from 
the website  
 
the hospital. The nurse recorded any questions asked by the patient after 
he/she had watched the video. This was followed by a 30-minute face-to-face 
counseling session based on the booklet and website information. 
 
The content of the educational video, patient booklet and internet website was 
based on the following learning objectives: CML as a disease, goals for TKI 
treatment, the importance of taking TKI medication as prescribed, and self-
management of adverse drug reactions. Patients were also taught how to use 
different adherence aids to remember to take their medication on time. They 
were also told about the psychosocial factors related to CML and the 
importance of social networking. Patients were asked to keep a diary on any 
adverse drug reactions and to score the severity of their symptom(s). Patients 
were also asked to keep a record of all new medication prescribed to them 
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during the follow-up period. All the educational material was placed on a 
limited-access website (www.kmlhoito.fi). Patients received their own 
username and password to access the site. The number of patient visits to the 
website was recorded daily. 
 
Patients were offered daily text messages to their mobile phones based on the 
dosing regimen of their treatment to help them remember the time to take 
their medication. They were also able to manage the text message settings from 
the website, e.g. change the timing of the message or, if they wished, stop 
receiving the messages altogether. 
 
????? ?????????????
?????? ????????????????????
In Study III the following step by step analyses were used: 1) quantitative 
comparison of patients with high and low adherence; 2) qualitative analysis of 
reasons for poor adherence in the group of patients that scored low in 
Morisky’s test; 3) model development of the CML patient journey based on the 
qualitative narratives and the previous model (Guilhot et al. 2013).  
The interview recordings were transcribed and analyzed using thematic 
analysis with abductive approach (Kylmä and Juvakka 2007). The purpose of 
the thematic analysis is to identify the important patterns and themes across 
the data that provide answers to the research question (Hämeen-Anttila and 
Katajavuori 2008). The themes used in the semi-structured interviews 
provided a framework for the analysis. The first step was to become familiar 
with the data. The important and interesting features of the data were then 
identified and labeled as codes. The codes were categorized into potential 
subcategories, themes, so that all relevant data were included. Finally, the 
themes were abstracted into broader categories that were named accordingly. 
Transcripts were coded independently by another researcher to ensure 
reliability. Codes and themes were then compared and discussed between two 
researchers (MK, VY) to make sure they were consistent. 
‘Patient journey’ was defined in the interview questions as the time before 
CML diagnosis, diagnosis, life after diagnosis and current situation. The 
different stages of the journey were analyzed from the patients’ stories and 
added to the patient journey model (Figure 11).  
 
???????????????????????????
In Study I the statistical analysis of the data was based on descriptive statistics 
calculated as frequencies, percentages, means, and medians. The kappa 
coefficient was calculated between the patient’s and the doctor’s assessment of 
adherence. 
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In Study II each patient’s MMAS score was compared with the quality of life 
score and symptom score. The statistical analysis was performed using IBM 
SPSS Statistics for MAC version 21.0 (IBM Corp, Armonk, NY, USA). 
Spearman’s rho test was used to test the difference between adherence, QoL 
and ADRs. For statistical analysis an α-value of 0.05 was considered 
statistically significant. 
In Study III the statistical analysis was performed using IBM SPSS Statistics, 
version 21.0. The quantitative variables were presented with mean, SD, median 
and percentages. Non-parametric statistical tests were used because the data 
were not normally distributed. Tests used for categorical data were Pearson’s 
chi-square (gender, employment status: working/not working, and usually the 
same doctor), and Fisher’s exact test (marital status: in a relationship/not in a 
relationship, number of TKI doses, and use of pill dispenser). The Mann 
Whitney U test was used for continuous parameters (age, age at diagnosis, 
time from diagnosis, number of doctor’s visits during the last 12 months, 
number of comorbidities and number of other medications).  
In Study IV the statistical analysis was performed using IBM SPSS Statistics 
for MAC version 21.0 (IBM Corp, Armonk, NY, USA). The baseline 
characteristics of the control and intervention groups were compared. Fisher’s 
exact test was used to compare non-continuous variables (MMAS class, MMAS 
questions, gender, education, TKI medication, treatment line, knowledge of 
the disease and treatment at baseline) between the groups. The Mann-Whitney 
U test was used to compare continuous variables (age, duration of the disease, 
MMAS score, number of co-morbidities, number of other medications) 
between the groups. These tests were not used to compare changes from 
baseline to follow-up. For this purpose we used the Wilcoxon signed rank test 
to compare changes within the groups. For statistical analysis an α-value of 
0.05 was considered statistically significant. Descriptive statistics included 
calculating frequencies, percentages, means and medians. 
?
?
?
?
?
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?? ???????
This chapter summarizes the key findings of the original studies (I-IV). 
 
 
????????????????????????
?????????????????????????????????????????
During the 15-month study period (from June 2012 to September 2013), 120 
patients were contacted in eight hospitals (four tertiary and four secondary 
care hospitals) (Studies I-III). A total of 86 patients participated in the study 
(approximately 20% of all Finnish CML patients). Twenty-seven patients 
declined and seven dropped out after the initial agreement because of a 
deterioration in their general health or because they had second thoughts. In 
this patient population the mean time from CML diagnosis was five years 
(median four years, range 1-17 years). The mean age at diagnosis was 53 years 
(median 52 years, range 19-79 years). Patient characteristics are shown in 
Table 6.  
 
????????????????????????????????????
Of the 86 patients enrolled, 43 were randomized into the intervention group 
and 43 into the control group before the baseline interview (IV). The groups 
were age and sex matched. A total of 68 patients completed the study (79% of 
the original study group): 35 in the intervention group (84%) and 33 in the 
control group (77%). Eighteen patients dropped out from the study during the 
nine-month follow-up. Of these, eight patients discontinued their TKI 
medication as they had been in optimal molecular response for more than two 
years (six in the intervention group and two in the control group). One patient 
from the intervention group was transferred to stem cell transplantation due to 
progression of the disease. Nine patients were lost or could not be contacted 
after the follow-up. 
In this patient population the mean time from CML diagnosis was 4.8 years 
(median four years, range 0.5–17 years). Most of the patients (81%) were 
receiving imatinib, 9% dasatinib and 10% nilotinib. Of the patients, 54% were 
on first-line and 28% on second-line treatment. The patients had an average of 
1.8 co-morbidities, the most common being high blood pressure and 
hypercholesterolemia in both groups. There was no difference between the 
intervention and control groups. 
 
?
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????????????????????????????????????????????????????? ???????????????????????????????????
?????????????
Variables   
 Gender, n (%)                          Male 45 (52.3) 
 Female 41 (47.7) 
 Agea     (years)                          Mean (SD)  57.8 (12.1) 
 Median 59 
 Range 25-83 
 Age at diagnosis (years)                 Mean (SD)  52.7 (12.3) 
 Median 52 
 Range 19-79 
 Time from diagnosis (years)                Mean (SD)  5.1 (3.7) 
 Median 4 
 Range 0.5-17 
   
Co-morbities and medications   
Number of other diseases                                      Mean (SD)   1.6 (1.5) 
 Median 1.0 
 Range 0-8 
Number of other cancers                                        Mean (SD)  0.1  (0.5)  
 Median 0 
 Range 0-3 
Number of other prescription medicines            Mean (SD)  2.1 (0.4) 
 Median 1.0 
 Range 0-10 
    
TKI medication related factors   
TKI medication, n (%)                          Imatinib 68 (79.1) 
 Dasatinib 9 (10.5) 
 Nilotinib 9 (10.5) 
   
Line, n (%)                          First 47 (54.7) 
 Second 25 (29.1) 
 Third 13 (15.1) 
 Fourth 1 (1.2) 
                                                            
Number of TKI doses per day, n (%) One 72 (83.7) 
 Two 14 (16.3) 
   
TKI medication taking time, n (%)                   Morning 27 (31.4) 
 Lunch time 23 (26.7) 
 Evening 21 (24.4) 
 Morning+evening 14 (16.3) 
 lunch+evening 1 (1.2) 
   
Visits and contacts with healthcare 
personnel 
  
MD visits in the last 12 months Mean (SD)  2.2 (1.8) 
 Median 2 
 Range 0-12 
MD visits during first year Mean (SD)  4.07 (1.5) 
 Median 4 
 Range 1-12 
Phone contacts in the last 12 months Mean (SD)  0.7 (1.7) 
 Median 0 
 Range 0-12 
   
Adherence aids   
Written treatment plan, n (%)                          No 86 (100) 
 Yes 0 
List of medications, n (%)                          No 82 (95.3) 
 Yes 4 (4.7) 
Doset, n (%)                          No 69 (80.2) 
 Yes 17 (19.8) 
Mobile phone reminder, n (%)                          No 76 (88.4) 
 Yes 10 (11.6) 
Knowledge total score, n (%)                                 0 28 (32.6) 
 1 30 (34.9) 
 2 15 (17.4) 
 3 7 (8.1) 
 4 4 (4.7) 
 5 2 (2.3) 
SD= standard deviation.  a At the time of adherence evaluation. 
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???? ????????????????????
 
Most of the patients (79%) were receiving imatinib, 11% dasatinib and 11% 
nilotinib and on first (55%) or second (29%) line treatment (Studies I-III). 
First-line treatment means that the patients were on the same active substance 
and dose as when they had started the treatment. Most (84%) of the patients 
were taking a single dose, usually in the morning (31%) or during lunchtime 
(27%). None of the patients had a written treatment plan and only 5% (n=4) 
had a list of their medications.   
Seventy-six percent of the patients had other diseases (mean 2, median 1, 
range 0-8). Eight percent of the patients had previously had a diagnosis of at 
least one other cancer (range 0-3). Due to these comorbidities the patients 
were also using other medications, the mean number of which was 2 (median 
1, range 0-10). 
Among patients who completed Study IV, most (81%) were receiving imatinib, 
9% dasatinib and 10% nilotinib. Of the patients, 54% were on first-line and 
28% on second-line treatment. The patients had an average of 1.8 co-
morbidities, the most common being high blood pressure and 
hypercholesterolemia in both groups. There was no difference between the 
intervention and control groups. 
?
???? ?????????????????????????
 
The response to TKI treatment was high (Study I), with 81% of the patients 
showing an optimal response according to European LeukemiaNet 2013 
recommendations (Baccarani et al. 2013). One-third of the patients had shown 
a major molecular response (MMR, MR3.0). The proportion of patients with 
MR5.0 was very high (23%).  
 
???? ????????????????????????
 
The CML patients’ knowledge of the disease and its treatment was poor as they 
scored on average 1 point out of the maximum 5 (Study I). One-third of the 
patients scored nothing from the questions, which means they did not 
understand their disease, how the medication works or the consequences of 
not taking the medicine as prescribed. Only 2% (n=2) of the patients scored 
the maximum 5 points. 
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???????????????????????????????????????
 
Thirteen physicians were involved in Study I. Twelve of them were specialists 
in hematology and one in internal medicine. The patients had had on average 
two MD visits during the last 12 months (median 2, range 0-12). There was no 
difference in the number of MD visits between different MMAS groups. Two-
thirds of the patients had a long-term relationship with their physician (67%), 
while the other 33% reported their physician changed every second visit.  
?
???????????????????????????????????????
 
Despite the high molecular response rates to TKI treatment, adherence 
according to MMAS was not good in most of the patients: less than a quarter 
(23%) of the patients showed high adherence, 56% medium adherence, and 
21% low adherence (Study I). Unintentional non-adherence was common, 
particularly forgetting to take the medication (48% of patients). One-fifth of 
the patients had sometimes forgotten to bring along their medication when 
leaving home or travelling. Patients in the present study had a low level of 
intentional non-adherence behavior. Stopping taking the medication when 
feeling worse after drug administration without telling the doctor was rare: 
only 11% had done so. Twenty-two percent of the patients reported taking their 
medication every day to be a real inconvenience (I, III).   
No significant statistical association/correlation was found between non-
adherent and adherent patients regarding gender, age, time from diagnosis, 
ADRs, knowledge, education, number of comorbidities or number of other 
medications. The patients with low adherence had fewer comorbidities (p= 
0.009) and concomitant medications (p=0.002) than highly adherent patients 
(III). 
There was a considerable difference between observed and experienced 
adherence: 94% of the patients were highly adherent according to the 
physicians’ assessment (I). The Kappa coefficient between patient’s and 
physician’s assessment of adherence was extremely low (-0.004), indicating 
that there was no agreement between the two assessments. Adherence was 
assessed by the physicians as medium in 5% of patients and low in only 1%. 
Compared to patient-reported adherence, the physician’s assessment was too 
optimistic in 73% of cases, realistic in 25% and pessimistic in 2%. In seventeen 
cases (20% of the total patient population) the physician had assessed the 
patient as highly adherent, whereas the MMAS scored patient adherence as 
low. In 45 cases (52% of the patients), patients whose adherence was medium 
according to MMAS were assessed by the physician as highly adherent (I). 
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????????????????????? ???????????????????????????
?????????????????????
 
The incidence of patient-reported ADRs was high (II). At the time of the study 
97% of the patients reported suffering from at least one ADR, which had 
started after the start of TKI treatment. The most commonly experienced 
ADRs were muscle soreness or cramp (69/86, 80%), swelling of hands, legs, 
feet, or around the eyes (59/86, 69%) and fatigue (43/86, 50%). The patient-
reported severity of ADRs was mainly mild to moderate. Thirteen patients 
reported their ADRs as severe. These symptoms were cramp (n=3), swelling 
(n=5), rash (n=3), diarrhea (n=1) and disturbed sleep (n=1). There were also 
differences in ADR profiles between the three different therapies (II). No 
correlation was found between adherence and patient-reported ADRs, because 
symptoms were equally common in each MMAS adherence class (high, 
medium and low). 
 
????????????????? ????????????????? ???
 
More than half of the patients felt the ADRs had a negative influence on their 
daily QoL (II). A quarter of the patients reported the symptoms had a negative 
influence either on their mood, general condition or enjoyment of life. Patients 
who felt their symptoms negatively affected their QoL suffered from an average 
of eight different symptoms (range 3-15, median 8). 
 
Compared with the total study population, the incidence of all symptoms other 
than nausea and vomiting was higher among patients who said their symptoms 
negatively affected their daily life than among those who reported no such 
influence (II). More men reported their symptoms to have a negative influence 
on their daily life than women (53% vs. 44%). More than half of the imatinib 
users (54%), one-third of the dasatinib users (33%) and one-fifth of the 
nilotinib users (22%) experienced symptoms which had an unwanted influence 
on their daily life. 
 
 
???? ????????????????????????????????????????????????
??????????????????????????????????????????????????
Both intentional and unintentional non-adherence to prescribed TKIs was 
reported, of which unintentional non-adherence was more frequent among the 
study patients. In a few cases patients reported intentional non-adherence as a 
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consequence of some unintentional reason. The most common reason for 
unintentional non-adherence was forgetting to take the medication (I, III). 
Based on the interviews, patients’ unintentional reasons for not to taking the 
medicine were forgetting, not having the medication with them, falling asleep 
early, and skipping a dose due to other illnesses (e.g. stomach upsets). 
Intentional reasons for not taking the medication as prescribed were ADRs, 
holidays, social events, changed dose and inability to schedule the medication 
regimen with fasting (III).  Women felt inconvenienced by their treatment plan 
more often than men. They also missed taking their medication due to reasons 
other than forgetting more often than male patients.  
 
“Now and then, if my morning is a bit out of the ordinary. Usually I take it in 
the morning, so if I’m somehow in a hurry or leave home at an unusual time, 
I might be in the car before I realise that, heck, I’ve forgotten it.” 
 
“And then I sometimes remember (the medicine) in the evening when I’ve 
already gone to bed, and if I haven’t eaten anything in the evening, I won’t go 
back upstairs to eat, I definitely don’t take them if I haven’t eaten. I’ve done it 
a few times, and then I get a nasty headache and don’t feel well, and it takes 
another hour before I feel better, so I just leave it; my husband doesn’t like it 
but I don’t always tell him.” 
 
A weekly pill dispenser used as a memory aid did not provide help for some of 
the patients using it; patients reported that they either forgot to fill it or that 
they still would forget to take the medication. Sometimes patients faced 
challenges in medication-taking that was beyond their control (e.g. stomach 
upsets). 
 
?????? ????
The high incidence of ADRs is described in Chapter 9.7. Patient interviews 
indicate that ADRs were the most commonly reported barriers to adherence. 
Several patients also reported skipping or reducing the dose due to ADRs.  
 
“In the morning after medication taking I felt awful. I was not able to do 
anything. I reduced the dose – and felt better”. 
 
 
 
 
 77 
??????????????????????
In the interviews, self-regulation of medication taking during holiday and 
traveling was often mentioned as the reason for deciding not to take the 
medication (III). Patients explained they did not want to think about their 
disease and routines around it or to deal with ADRs while traveling. Socializing 
was another reason for skipping the dose or changing the taking time to avoid 
ADRs. Some patients reported sometimes remembering their daily medication 
too late, for example when they were already in bed or if the taking time was 
timing to take the medication with food or in a fasting state was challenging 
and contributed to skipping the dose.  
 
“Usually, if we are going to a party or have a day off, for example, I will take 
the medicine already in the morning or skip it. You never know, if you are 
going to get headache or nausea or something else.. It’s not nice, when you 
are not feeling well. I understand I should take the medicine, but if there is 
that kind of situation, I will not take them”.  
 
 
?????????????????????????????????????????????
All CML patients in the study were lacking the therapy plan and only a few had 
the medication list (I, III). It was found in the knowledge test (I, III) that 
patients did not fully understand the disease and its treatment. On the other 
hand, understanding the consequences of not taking the medication and the 
goal of the treatment were regarded as motivating factors by the patients with 
low adherence to adhere to their medication (III). 
 
“Of course it’s motivating if you have a goal. I like it that for instance 
experienced doctors tend to sort of give you a goal to aim for or say that 
we’re trying to reach a value that’s lower than that... Of course it’s been 
helpful to know that they’re keeping an eye on how this is going.” 
 
?????? ????????????????????????????????????????
??????????
 
At the baseline the groups were similar in adherence as assessed by MMAS 
class (Fisher’s exact test p>0.05). No change in adherence was observed in half 
of the patients, while in 27% adherence decreased over time. The change from 
baseline to follow-up in the control group was statistically non-significant 
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(Wilcoxon signed rank test, p=0.593). In the intervention group adherence 
remained the same in half of the patients, but improved in 49% (Wilcoxon 
signed rank test, p<0.0001). 
 
Eight patients in the intervention group and seven in the control group were 
already highly adherent and had a maximum MMAS score (8) at baseline. The 
MMAS score of six (86%) of these patients declined during the follow-up in the 
control group, compared with only one patient (13%) in the intervention 
group. 
 
In the intervention group the MMAS score increased more often (21/35) than 
in the control group (11/33) (60% vs. 33%, respectively, Mann-Whitney U test, 
p= 0.001). The MMAS score declined in almost half (49%) of the patients in 
the control group, but in only 9% of those in the intervention group (Mann-
Whitney U test, p=0.001).  
 
 
???????????????????????????????????????????????
The point that the patients remembered most often from the intervention in 
the follow-up interview was, “One has to take the medication as prescribed, on 
time” (14/35). A majority of the patients (30/35) found the education useful, 
the most useful parts being face-to-face counseling (30/35), the educational 
booklet (29/35) and the video (25/35). On average 23 patients visited the 
website per month. Seven patients had forgotten the content of the education, 
explaining that this was mainly due to their advanced age and memory 
impairment.  
One-third (n=11) of the patients chose to receive the tailored daily text message 
reminder. Only three of them (27%) perceived the text message as useful. One-
third thought the text message interrupted their daily routines. The reason 
reported for not wanting the text message reminder was “no need” in all cases. 
  
 
????????????????????????????????????????????????
The main findings of the patient journey are described in Figure 11. 
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??????????????????????????????? ????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????? 
?
??????? ?????????????????????????????????????????????????????????
Most patients were asymptomatic when diagnosed with CML. In many cases 
the disease was unexpectedly diagnosed after a routine physician visit. The 
majority of the patients (94%) experienced the diagnosis as “shock, crisis or 
the end of the world”. One-third of the patients were told of the diagnosis on 
the phone. Patients would have preferred to hear ‘the bad news’ face to face 
from their doctor.  
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The information patients received about CML from the doctor at the time of 
diagnosis varied amongst the patients: 38% (7/18) felt they received adequate 
information about CML and its treatment, almost two-thirds (11/18) did not 
think they got enough information, and one patient had received incorrect 
information.  
The patients said it was important to receive information that was supportive 
and encouraging, highlighting the facts that CML is a well-studied, chronic, 
treatable disease with effective medication and can be managed at home. It 
was important to use non-technical language. Patients preferred the doctor’s 
way of avoiding the word ‘cancer’ and referring to a serious but treatable 
chronic condition instead. One patient even felt that the doctor had been 
understating the seriousness of CML by saying it is not as bad as it sounds. A 
few patients felt they received too much information to handle too soon. In 
most cases the provision of adequate information relieved the patients’ fear of 
death and the severity of the situation. Some of the patients had negative 
experiences regarding the way the information was given. A few felt that the 
doctor did not have sufficient knowledge of the disease (III). 
To learn more about CML and to understand the disease better, patients had 
searched for information from different sources. Ten of the patients had 
actively sought more information about the disease. The internet was the most 
commonly used tool, half of the patients having used it to find out more about 
CML itself, the treatment and other CML patients’ experiences of the disease. 
Other information sources used were brochures provided by the hospital or 
mailed home, and library books. Understanding more about the nature of CML 
was important for the patients and made them feel more comfortable about 
dealing with the disease. However, two patients said they did not want to learn 
more about CML or needed more time to be ready to receive information.  
The patients were not aware of what caused the disease and what was 
happening in their body or how the medication works (I, III). Few of the 
patients understood the consequences of not taking the medication. This was 
seen as a factor motivating them to adhere to the treatment. The knowledge 
scores of patients who had reported they had searched for information by 
themselves were better than those of patients who did not seek more 
information. 
 
??????? ??????????????????
The majority of patients with poor adherence said they were very pleased with 
their healthcare personnel and the treatment received in general (III). 
Interactions with doctors and nurses were important during the diagnosis and 
follow-up appointments. Two-thirds of the patients usually saw the same 
doctor. Both informational and emotional support from the doctors and other 
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healthcare personnels had a positive influence on the patients. Especially at 
the beginning, when there were lots of concerns and questions about the newly 
diagnosed CML, the doctor’s support was considered important. Support 
consisted of discussing with the doctor about the disease, its prognosis, the 
treatment and its goals, and ADRs in an encouraging way. It was also 
important that the doctor was knowledgeable and had time to talk in person. 
For the patient it was reassuring to know that if there were any concerns they 
would always get addressed. 
A lack of interaction and information from the healthcare personnel had a 
negative impact on patients. Frequently changing doctors meant there was no 
continuous support. Six patients said they were not informed about the 
available services such as psychologists, social workers or other support 
provided by the hospitals. Services were not always easily available. Laboratory 
results were often sent to patients by mail. In many cases patients said they did 
not understand the results.  
Patients who felt they did not receive any mental support from the hospital still 
thought that their care was good and taken seriously. The care provided by the 
hospitals was considered excellent by all the patients. One stated, “You feel you 
are in good hands there”. 
 
?????????????????????????
Even though only 44% of the low-adherent patients in the study experienced 
the TKI treatment as inconvenient, most of the patients (94%) said they were 
willing to stop taking the medication in the future if possible (see Chapter 3.7, 
III).  
 
??????? ?????????????????????????
The key findings of the study are presented in Figure 12. 
?
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?
???????????????????????????????????????????????????????????????????????????????????????
?
?
?
?
?
?
?
Adherence Experiences on patient journey (III) 
Adherence was low (I) Diagnosis experienced as crisis or end of life  
Physician’s assessment too high (I) Information at the time of diagnosis insufficient  
Forgetting most common reason for 
non-adherence (I, III, IV) 
In general satisfied with healthcare 
Need to understand the goal of treatment 
Self-regulation (III) 
Good treatment responses despite of 
poor adherence (I) 
 
 
 
Patient  
  Knowledge of disease and its treatment poor (I) 
  Willing to take medication (I-II) 
 
ADRs & QoL (II) 
High prevalence despite of 
adherence level Intervention (IV) 
Affect to QoL Intervention improved adherence 
Without intervention adherence behaviour tended to 
decline 
Partnership/Support (I, III, IV) 
Especially intentional non-adherence improved in 
intervention group 
Lack of written treatment plans  Patients preferred face-to face counseling  
Lack of medication lists  
Lack of psychological support (III)  
?
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??? ???????????
This thesis investigated the patient journey and medication adherence of 
patients with CML undergoing treatment with TKIs in Finland. This work 
consisted of two parts: a literature review and an empirical part. 
 
In the literature review, evidence on the non-adherence of CML patients to 
TKIs was examined (see Chapters 2, 3 and 4). The first studies on the QoL 
associated with TKI treatments (Chapter 3) have been published during the 
last years and new assessment tools have been developed. The level of 
adherence of CML patients and the reasons for patients’ non-adherence have 
also been widely studied in recent years (see Chapter 5). Unfortunately, 
publications on interventions to improve the medication adherence of CML 
patients to TKIs are lacking. In view of this, the literature review discussed 
interventions to improve medication adherence in general (see Chapter 5). 
The empirical part (later study) of this thesis focused on the patient journey of 
CML patients in Finland: patients’ experience on their journey with CML, 
adherence to TKIs, patient-reported ADRs, and QoL (Studies I-IV). These 
perspectives were chosen because they are relevant for understanding the 
background and consequences of adherence. Currently, the literature provides 
no information on these aspects of care in Finland and even the evidence from 
other countries is limited. Finally, the influence of tailored patient education 
on adherence to TKI medication among patients with CML was investigated 
through a controlled intervention study (Study IV). 
The study employed a novel approach to adherence assessment by CML 
patients and their physicians. We found the same, quite low patient-reported 
adherence to TKI treatments that has been found in most previous studies 
(Noens et al. 2009, Marin et al. 2010b, Ibrahim et al. 2011). From the 
physician’s perspective this study provides new information on the discrepancy 
between patient-experienced and physician-observed adherence. In most of 
cases with low patient-experienced adherence, physicians estimated adherence 
to be high.   
This study provides new information from the patient’s perspective on the 
prevalence of patient-reported ADRs during TKI treatment (II). This 
prevalence was high and much higher than in clinical trials, which in most 
cases study the efficacy and safety of treatments. Even though the ADRs did 
not influence adherence, they had a significant influence on patients’ QoL. The 
findings also provide new information about patients’ experiences on their 
journey with CML (III). 
 
A lack of interaction and information from healthcare professionals had a 
negative impact on non-adherent study patients (III). Frequently changing 
doctors meant there was no continuous support. Laboratory results were often 
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sent to patients by mail. In many cases patients reported they did not 
understand the results. Nevertheless, the overall care provided by hospitals 
was considered excellent by all patients.  
The ability to cope with different stages on the patient journey has been found 
to be affected by the degree of knowledge about the disease and comfort level 
with the physician (Guilhot et al. 2013). The present study provides new 
information on patients’ knowledge of the disease and its treatment, which was 
poor irrespective of adherence level (I, III). Few patients understood the 
consequences of not taking the medication. Understanding the treatment goals 
was seen as a motivating factor to adhere to the treatment. A real partnership 
between healthcare professionals and patients would improve patients’ 
abilities to follow their treatment plans. 
It appears that this is the first study assessing the impact of tailored patient 
education on the medication adherence of patients with chronic phase CML. 
Tailored patient education improved the adherence of patients with CML after 
a 9-month follow-up (IV). Without the additional support, adherence behavior 
tended to decline. Most of the patients with CML involved in the study found 
enhanced patient education and adherence support useful. This study also 
provides new information on patients’ preferences regarding education and 
adherence aids. Most valued was face-to-face counseling by a hematology 
nurse. The information booklet focusing on the basic facts about CML and its 
treatment with TKIs was perceived almost as useful as face-to-face counseling. 
Clearly least valued were text message reminders. This indicates that patients 
with CML need personal contact and communication with their healthcare 
providers. They also need easy access to written information tailored for their 
specific needs. 
 
?
????? ???????????????????????????????????????????
??????? ?????????
?
We found the same, quite low patient-reported adherence to TKI treatments 
that has been found in most previous studies (Casamartina et al. 2010, 
Ibrahim et al. 2011, Marin et al. 2010a, Marin et al. 2010b, Koren-Michowitz et 
al. 2012). 
 
According to our findings, physicians seem to be too optimistic in assessing 
their patients’ adherence (I). Previous studies with other patient groups and 
medications show that physicians are inaccurate in assessing adherence and 
judging which patients are adherent and which are not (Wagner 2001, 
Osterberg and Blaschke 2005, Zeller et al. 2008, Noens et al. 2009). When 
estimating the degree of adherence for any particular patient group, physicians 
have been shown to be accurate only 10–40% of the time, for both medication 
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and other treatments (Turner and Hecht 2001, Parker et al. 2007, Morton et 
al. 2008). In the Belgian ADAGIO study physicians believed that on average 
93% of CML patients on imatinib were adherent during the first month after 
diagnosis and that 87% were adherent after one year of treatment (Noens et al. 
2009). 
 
One reason for this discrepancy in adherence estimates by patients and their 
physicians may be clinical treatment outcomes. Despite the low patient-
reported adherence rate assessed by MMAS, most of the patients (81%) had an 
optimal molecular response to their treatment according to ELN 2013 
Guidelines (Baccarani et al. 2013). Consequently, we assume that good clinical 
treatment outcomes were the reason why the physicians gave a higher estimate 
of adherence than the patients. On this basis, we also assume that in many 
cases physicians’ estimates of adherence are based primarily on evaluation of 
treatment outcomes as indicated by clinical laboratory tests. Our findings also 
suggest that patient-experienced adherence can be low even though the clinical 
treatment response is optimal.  
?
 
 
??????? ????????????????? ????? ???? ?????? ?????????? ??? ???????????
??????????
 
As CML patients come to expect increasingly longer survival with TKI therapy, 
the importance of managing symptom burden related to the disease and its 
treatment will also increase.  It has been reported in previous studies that 
symptom burden is cited as a primary reason for poor adherence to TKI 
therapy, while poor adherence has been linked to unsatisfactory treatment 
response and increased healthcare resource utilization (Noens et al. 2009, 
Marin et al. 2010, Eliasson et. al 2011).  
 
Only 10% of the patients in the study (II) spontaneously reported ADRs had 
influenced their medication taking, i.e. they had stopped taking the medication 
or reduced the dose when feeling worse. Patients were willing to take the 
medication even though they were reporting ADRs. The complex interplay 
between symptom burden, adherence, response to TKI therapy, and healthcare 
utilization highlights the need for regular symptom burden assessment in CML 
as a means to identify potential adherence problems before they affect the 
patients’ response to TKI treatment. Information on the disease and 
treatment-related effects from the patient’s perspective crucially provides the 
additional knowledge needed for both patients and physicians to make 
informed treatment decisions. Many patients do not exhibit disease symptoms 
at diagnosis, and therefore may be irritated by the ADRs caused by the 
treatment.  
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???????????????????? ????????????????? ???
 
We were unable to find a clinical correlation between ADRs and patient non-
adherence, but there was a significant correlation between higher number of 
symptoms and a negative impact on the patient’s QoL (II).  
 
Results from previous randomized controlled trials suggest that treatment 
decisions influenced by QoL considerations may be beneficial in some patients 
(Hahn et al. 2003). It has been shown in previous studies that treatment with 
TKIs generally does not adversely affect – and may even improve – patient 
QoL (Basch et al. 2009). As stated by the FDA, some “treatment effects are 
known only to the patient” and such information can be lost when the patient’s 
perspective “is filtered through a clinician’s evaluation of the patient’s response 
to clinical interview questions” (FDA 2009). Thus it is likely that robust QoL 
evidence in this area will help physicians to make more tailored treatment 
decisions. In some therapeutic areas, symptom-specific rating scales have been 
found to be valuable tools for assessing the effects of an intervention on 
treatment-related symptoms. In general, patients report symptoms earlier and 
more frequently than clinicians. From these studies, it appears that clinicians 
may be better at recognizing ADRs with potentially serious consequences, 
whereas patients may be better at assessing more subtle changes that affect 
their overall QoL. 
 
The emergence of treatment-related ADRs, although potentially detrimental to 
patient QoL, can be managed effectively in most cases because ADRs are 
mostly mild to moderate in severity and generally consistent (i.e. predictable) 
over time and across lines of therapy. Furthermore, the number of TKIs 
currently approved for the market increases the likelihood that patients found 
to be intolerant to one TKI can switch to another, better tolerated alternative. 
 
??????? ????????????????????????
?
In this study, knowledge of the disease and its treatment was poor irrespective 
of the adherence level (I, III). Few patients understood the consequences of 
not taking their medication. Understanding the treatment goals was seen as a 
motivating factor to adhere to the treatment. A real partnership between 
healthcare professionals and patients would help patients to better follow their 
treatment plans. 
 
????????????????????????????????????????????????????????
 
It has been reported in previous studies that adherence to TKIs declines with 
time (Noens et al. 2009, Abraham et al. 2008). Our finding was the opposite: 
non-adherent patients in the study were more recently diagnosed than 
adherent ones (I-IV). Additionally, patients with suboptimal adherence were 
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younger, and therefore more often at work. We were not able to find a 
statistically significant correlation between non-adherence and gender, age, 
time from diagnosis, adverse effects, knowledge or education as published in 
many previous studies (Noens et al. 2009, Eliasson et al. 2011, Efficace et al. 
2012a). However, the reasons for non-adherence were similar to those found 
in these other CML-related studies. Forgetting to take the medication was 
common. This is a human phenomenon, related to the fact that patients have 
so many other things in their lives competing for their time and attention than 
medication taking. 
  
 
??????????????????????  
 
In this study we developed a patient journey model. The model, which is based 
on the experiences of CML patients with low adherence, helped to identify the 
critical phases in the CML patient’s journey, such as getting the diagnosis, 
starting the treatment, getting continuous support for self-management of the 
treatment, and managing with the fear caused by the perceived severity of the 
disease. This is unique and provides further knowledge of the factors 
contributing to low adherence. This kind of integrated understanding is 
needed to influence the system-based factors that prevent low adherence from 
occurring with TKI treatment. The first crucial step in the CML patients’ 
journey was found to be getting the diagnosis. This represented a crisis for all 
patients with low adherence and is in line with the study by Guilhot et al. 
(2013). More attention should be paid to the way patients are told of the 
diagnosis and how they are emotionally supported to cope with the shocking, 
unexpected news, as quite a number of the study participants criticized the 
current way of doing it. In many cases the patient was informed of the 
diagnosis by phone and then invited to come to the hospital for the start of 
treatment. This increased their negative emotional load. Also, the information 
provided at the time of diagnosis was insufficient. This concerned not only the 
disease and its treatment, but the available support services, such as 
psychologists and social workers. It seems that for many patients non-
adherence could be prevented by supporting them at the very beginning of 
their journey: give them more psychological support, involve them in the 
treatment and its goals, and provide them with written treatment plans and 
medication lists. It is important to build a bridge between the healthcare 
system and patients taking their medicines at home and to ensure the 
continuity of support throughout the journey. 
 
 
???????? ??????????????????????????????????????????????????
 
The patients with CML involved in the study did not regard text message 
reminders to be as important as other adherence aids (IV). Many previous 
studies have shown positive results with text messages as sole adherence aid 
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(Lester et al. 2010, Castano et al. 2012, Foreman et al. 2012, Wald et al. 2014, 
Khonsari et al. 2015). As those studies have not compared different adherence 
aids nor assessed patients’ preferences, they do not provide comparative 
evidence of the perceived usefulness of the various adherence aids. It is 
important to understand and consider patients’ perceptions and preferences 
when designing patient education interventions for real-life clinical practice. 
Otherwise, adherence aids may favor, say, electronic reminders, whereas 
patients want to meet their nurse or other healthcare provider. 
 
The top three patient information priorities found in a systematic review of 
thirty studies involving patients with different cancers were related to 1) 
prognosis, 2) diagnosis, and 3) treatment options (Tariman et al. 2014). The 
authors suggest these topics could serve as a start to elicit CML patients’ 
information needs and guide patient education across the patient journey. 
Being able to prioritize the most-needed information can make patient 
encounters more meaningful and useful (Tariman et al. 2014). Patients in the 
present study were willing to take their medication, but unfortunately the 
system-related factors/tools (written treatment plan, medication list) used to 
support self-management and medicine taking at home were lacking in all 
cases (I, III). Their non-adherence could be at least partly prevented by better 
involving them in the treatment and its goals with written treatment plans and 
medication lists.  
 
 
????? ?????????????????????????????
??????????????????????????
This study involves insights into the journey of 86 CML patients taking TKIs. 
As the patients come from eight hospitals operating in different parts of 
Finland the study provides quite a good overview on the quality of CML care 
from the patients’ perspective in Finland. The study participants represented 
20% of all Finnish CML patients and involved 13 physicians specializing in 
CML care.  
Due to the possibility of biasing factors our results do not necessarily reflect 
the complete picture of TKI adherence in Finland. There may have been more 
non-adherent patients declining to participate during the study enrolment 
period, thus resulting in increased selection bias. However, the highly 
standardized data gathering procedure and personal interviews conducted by 
one person meant there was no inter-observer bias. On the other hand, the 
method used to obtain physicians’ subjective assessments of their patients’ 
adherence is not well standardized and includes the risk of inter-observation 
bias. In clinical practice, however, the high risk of a subjective overestimation 
of TKI adherence in individual patients is more relevant.  
 89 
Because of the large amount of transcription data (86 patients), the qualitative 
analysis was intentionally focused on those patients with low adherence to 
their TKI treatment (n=18). Thus, the present study provides no evidence on 
how patients with higher adherence scores differed in their experiences and 
behaviors from those with low adherence scores as measured by MMAS.  
 
??????? ????
The 8-Item MMAS shows three different adherence rates (Morisky at al. 
2008). Patients with the rating 2 or 3 (medium or low) are not ‘fully’ adherent. 
In our study this represented 77% of the patients (I-IV). The patient needs to 
score all eight points to be highly adherent according to MMAS. This might 
influence the results. MMAS has not been specially developed for the 
evaluation of medication adherence in CML patients, although it is widely used 
in other chronic illnesses. It would be interesting to validate a CML-specific 
adherence scale in the future. Almost all of the physicians’ assessments were 
‘high adherence’, which caused bias in the comparison between experienced 
and observed adherence (I). We were therefore unable to perform any 
statistical analysis between these two assessments. This should be addressed in 
future studies.  
 
 
????????????????????????
A semi-structured interview method with pre-defined key topics and themes 
was used (I-IV). The interviews were conducted using a flexible structure, 
which allowed conversational, two-way communication between interviewer 
and interviewee (Mason 2004). All the patients participated in two in-person 
interviews with the same investigator (MK) (baseline and at nine months), 
which is a unique approach. The interviews were audiotaped and transcribed 
verbatim by a professional transcriber.  
 
????????????????????
 
As the adherence rate was the same in the intervention and control groups at 
baseline, it was possible to observe whether the adherence rate improved with 
enhanced support or declined without it over the 9-month period (IV). It was 
evident that the adherence rate tended to decline without support. This 
indicates that patients with CML on long-term therapies need continuous 
support to retain their motivation to regularly take their medication. 
 
Because few published studies have addressed adherence improvement 
techniques in patients with cancer, methods described for the general 
population in previous studies have been extrapolated for this group of 
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patients (McCue et al. 2014). Patient education interventions, including a 
combination of face-to-face counseling and interactive technologies or videos, 
have proved to be the most effective (Gysels et al. 2004). For this reason 
patient education in the present study was designed as an entity made up of 
different empowering adherence aids supporting patient self-management and 
creation of a partnership with nurses. 
Crucial aspects for the scientific rigor of Study IV were 1) the controlled study 
design with an appropriate number of participants randomly allocated to the 
study group and control group, 2) carefully planned educational intervention 
applying a relevant combination of adherence aids, 3) standardization of the 
delivery of the intervention in all eight hospitals involved in the study by 
training the nurses and providing them with the same resources for patient 
education, 4) having a follow-up period long enough to measure the impact of 
the intervention on medication adherence, and 5) applying a validated 
quantitative measure for adherence assessment completed during qualitative 
patient interviews to assure face-validity and high participation rate. As the 
data sets were complete for each patient, 6) we did not need to make 
adjustments in the data analysis for missing data, 7) all data was collected by 
one author (MK) in order to standardize the data collection procedure. And 
finally, 8) nurses who delivered the intervention did not meet patients 
allocated to the control group (standard treatment) in order to avoid dilution 
of results. 
 
 
??????? ??????? ??????????????
The study was cross-sectional (patient interviews conducted at baseline) (II). 
ADRs were only reported by the patient and not compared with the physician’s 
assessment. 
The instruments used for assessing ADRs and QoL were not validated (II). At 
the time this study was started, no validated QoL assessment instruments 
specific to leukemia or CML were available. Recently however, three leukemia- 
and CML-specific QoL instruments have been validated: the FACT-Leu (Trask 
et al. 2013), the MDASI-CML (Williams et al. 2013) and the EORTC QLQ-CML 
(Efficace et al. 2014a). The further development and validation of leukemia- or 
CML-specific QoL measurement tools could improve the overall management 
of CML. 
?
?
?
?
?
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?????????????? ?????????? 
?????? ???????????????????????????????????????????????
CML has changed from a fatal to a chronic disease during the last decade. 
Nowadays the patient is fully responsible for managing the treatment at home. 
This change presumes a new type of co-operation and partnership between the 
physician and the patient. The physician is the medical expert when it comes to 
the illness and its medication, while the patient best understands his/her 
everyday life with the disease and its treatment. It is important to understand 
the root causes of patients’ non-adherence in order to encourage them to take 
responsibility for their own treatment. Further research is needed to 
understand these changes in the medication management processes of CML 
patients arising from current advances in pharmacotherapies. 
Controlled studies assessing adherence over time with repeated measurements 
are needed to provide a better understanding of adherence behavior and its 
changes. Additionally, identifying risk factors for clinically significant declines 
in adherence will allow effectively targeted interventions to maintain high 
adherence and avoid the adverse consequences of poor adherence. It would be 
interesting to evaluate the severity of the symptoms in future studies.  
Future studies should apply methods and study designs that will provide more 
comparative evidence on the effectiveness of different kinds of adherence aids 
from the patient’s perspective. 
 
?????? ???????????????????????????????????
As demonstrated in this thesis, sub-optimal adherence to TKI therapy in CML 
is a widespread problem that may compromise treatment outcomes. 
Physicians and healthcare professionals have a key role to play in promoting 
adherence among patients through assessment, communication, education 
and personalized solutions. 
The findings of the intervention study (IV) have implications for the training of 
nurses and other healthcare providers, as well as for organizing patient 
education and adherence support as an essential part of patient care. More 
should be done to involve patients in the planning of adherence support and in 
applying different adherence aids, even the most innovative digital ones. 
Organizational development is needed as well, so that patient education and 
adherence support can be integrated into standard care.  
Simple measurement tools such as MMAS might be helpful in identifying some 
of the adherence problems in clinical practice. MMAS is a short and easily used 
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tool applicable to routine practice. In this study MMAS questions were asked 
verbally in interviews (I-IV). We suggest that this approach can give more 
information than asking the patient to fill in a form. More important than the 
numeric value of adherence is the information that the eight items provide 
about medicine use. The MMAS’s eight items indicate intentional and 
unintentional reasons for non-adherence and could help physicians and nurses 
to evaluate adherence, identify adherence problems and discuss them with the 
patient. It is important to train physicians and other healthcare providers 
about adherence and its role in managing medication use in clinical practice.  
The ADRs that had the most negative effect on patients’ QoL in the present 
study were swelling, rashes, disturbed sleep, feeling sad or depressed, 
problems remembering things and a feeling of malaise (II). Identifying these 
symptoms could help in treatment follow-up designed to manage ADRs and to 
help patients to continue their treatment successfully. Good QoL is necessary 
to support the proper use of TKI therapy in CML.  
Intentional self-regulation of medicine taking seemed to be related to 
managing ADRs in situations where they would have prevented normal life, 
e.g. participation in social events (III). It is important to educate patients to 
know the limits of self-regulation as it is part of the journey: how many doses 
can be skipped and how often without jeopardizing treatment outcomes. This 
kind of communication to improve the patient’s ability to follow the treatment 
plan throughout the journey requires a real partnership between healthcare 
professionals and the patient.  
The patient journey model developed in this study helped to identify the 
critical phases in the CML patient’s journey and provides further knowledge of 
the factors contributing to low adherence (III). This kind of integrated 
understanding is needed to influence the system-based factors that prevent 
poor adherence from occurring with TKI treatment.  
It seems that for many patients non-adherence could be prevented by 
supporting them at the very beginning of their journey: give them more 
psychological support, involve them in the treatment and its goals, and provide 
them with written treatment plans and medication lists (I, III). These simple 
tools could also increase patients’ knowledge of CML as a disease and its 
treatment, which was found to be poor in our study. Solving these medication 
management-related issues may require physicians to be more aware of a 
range of factors related to adherence and self-management of long-term 
diseases, such as CML, requiring patients’ active involvement. It is important 
to build a bridge between the healthcare system and patients taking their 
medicines at home and to ensure the continuity of support throughout the 
journey. 
Our findings indicate that access to personal counseling and information 
should be systematically planned as an essential part of CML care (IV). Each 
patient with CML should have a customized support plan based on their 
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special needs. These tailored support plans should recognize that the need for 
support varies in different phases of the disease and between patients (Ryan et 
al. 2014). To achieve these goals in practice requires healthcare providers 
involved in CML care to be capable of creating a therapeutic alliance with their 
patients so that the patients can develop the problem-solving skills needed in 
the self-management of CML with TKIs. Another requirement is the 
availability of appropriate and updated information in printed and electronic 
formats.  
Successful pharmacotherapy requires communication and planned 
collaboration between physicians, nurses, pharmacists and patients. It is 
therefore important to combine different types of adherence aids, such as 
those used in the present study, and to train healthcare providers in adherence 
and its role in managing medication use in clinical practice (IV). The patient 
journey model might also help in identifying each patient’s personal needs 
(III). 
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????????????????
This study found that patient-reported adherence to TKI treatments in Finland 
is the same as that found in the majority of previous studies, 21% having low 
adherence as measured by MMAS. However, there seems to be a very weak 
agreement between the patient’s and the physician’s assessment of adherence, 
physicians having a tendency to overestimate adherence in CML patients. This 
may be related to the finding that physicians based their adherence estimation 
primarily on the patients’ clinical treatment response. Despite a good clinical 
response, patients may lack knowledge of CML as a disease and its treatment 
with TKIs, as well as access to a treatment plan and medication list (I). 
TKI-related ADRs were common among CML patients irrespective of 
medication adherence level. Patients who reported that ADRs had a negative 
influence on their daily QoL experienced more ADRs than those who did not 
report a negative influence (II). 
The patient journey model developed in this study helped to identify critical 
phases in the CML patient’s journey influencing adherence, the first of them 
being getting the diagnosis. It is important to educate patients about self-
regulating their TKI medication, including managing ADRs, as self-regulation 
is part of their journey and a contributor to non-adherence. Communication to 
improve patients’ ability to follow their treatment plan throughout the journey 
requires a real partnership between healthcare professionals and patients (III). 
Tailored patient education improved the medication adherence of patients 
with CML. Without this support, adherence behavior tended to decline. 
Personal communication with a nurse proved to be an essential part of 
adherence support and should not be ignored despite the growing number of 
digital adherence aids. It is important to understand and consider patient 
perceptions and preferences when designing patient education interventions 
for real-life clinical practice in the future (IV). 
?
?
?
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